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Abstract 
 Osteoarthritis (OA) is a highly common articular disease whose prevalence is 
associated with several risk factors, like age, obesity, genetic predisposition and prior 
joint injury. Chronic pain is the most striking symptom of this condition, being the 
main complaint presented by patients, therefore, the main clinical concern is its 
treatment. OA is considered an inflammatory and nociceptive disease but recent 
studies have been pointing towards the possibility of a neuropathic component in the 
mechanisms of pain associated with the disease. Indeed, studies from our group using 
both the monoiodoacetate- (MIA) and the collagenase-induced models of OA have 
found an increase in the number of primary afferent neurons expressing markers of 
neuronal damage, in ipsilateral dorsal root ganglia (DRG). In both models an 
increased expression of regeneration associated-genes (RAGs) was also observed. In 
the collagenase-induced OA model a significant increase in the expression of the 
RAG small proline rich protein 1A (SPRR1A) was observed. Taking into account 
these findings, we investigated the potential contribution of SPRR1A overexpression 
on the nociceptive behaviour of OA animals.  
For this purpose, a viral vector engineered to express SPRR1A (AAV2/5-SPRR1A) 
was intra-ganglionically injected in OA and control animals. Besides it, AAV2/5 
expressing Green Fluorescent Protein (AAV2/5-GFP) and saline were as well injected 
in DRG of other groups of animals. During the following 4 weeks the animals´ 
nociceptive behaviour was assessed trough the Von Frey, CatWalk and Knee-Bend 
tests, as well their motor coordination, by using the rotarod test. Indeed, OA animals 
injected with AAV2/5-SPRR1A revealed attenuation in their nociception and gene 
expression studies confirmed the great increase of SPRR1A mRNA levels in the DRG 
of control and OA animals. However, an unequal SPRR1A expression was found, 
with ipsilateral DRG of control animals revealing a much greater overexpression. 
ATF-3 and GFAP mRNA levels showed as well a higher increase in the ipsilateral 
DRG of control animals following AAV2/5-SPRR1A injection. The knees of these 
animals showed a slight erosion of the cartilage and consequent exposure of the 
subchondral bone, detected by histological analysis. The animals injected with 
AAV2/5-GFP or saline showed minor nociceptive behaviours due to the intra-
ganglionic surgery procedure, which were progressively resolved after the first week 
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following injection. Additionally, although OA animals injected with AAV2/5-GFP 
or saline have shown the maintenance of nociceptive behaviours, their ipsilateral 
DRG, as well those of control animals, showed high levels of SPRR1A mRNA, 
probably due to the highly invasive surgical procedure.  
Data suggest SPRR1A plays an important role in the peripheral events leading to the 
development of nociceptive behaviour in experimental models of OA. Targeting its 
expression in the DRG, namely by enhancing it, might be a potential approach for 
pain attenuation, possibly by promoting regenerative mechanisms within the sensory 
ganglia. However, further studies are still necessary to evaluate the molecular 
mechanisms behind SPRR1A role and to develop less invasive delivery routes for 
gene targeting in the DRG. 	  
Keywords: Osteoarthritis (OA), Dorsal root ganglia (DRG), Regeneration-associated 
genes (RAGs), small proline rich protein 1A (SPRR1A), AAV2/5-SPRR1A, intra-
ganglionic injection 
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Resumo 
 A osteoartrose (OA) é uma doença articular extremamente comum cuja 
prevalência está associada a vários fatores, como idade, predisposição genética e 
existência de lesão articular anterior. A dor crónica é o sintoma mais marcante desta 
condição, sendo também o que é mais reportado pelos doentes, pelo que a maior 
preocupação clínica é o seu tratamento. A OA é considerada uma doença inflamatória 
e nocicetiva mas estudos recentes têm apontado para a possibilidade de um 
componente neuropático nos mecanismos da dor associados a esta patologia. De 
facto, estudos do nosso grupo usando a injeção de monoiodoacetato (MIA) e 
colagenase como modelos de indução da OA encontraram um aumento no número de 
neurónios aferentes primários que expressam marcadores de lesão neuronal, nos 
gânglios raquidianos ipsilaterais. Em ambos os modelos foi também observada uma 
expressão aumentada de genes associados à regeneração (RAG, de regeneration 
associated-genes). No modelo de OA induzido pela colagenase foi observado um 
aumento significativo da expressão da pequena proteína 1A rica em prolina 
(SPRR1A, de small proline rich protein 1A), que pertence à família dos RAG. Tendo 
em conta estes dados, nós investigámos o potencial efeito da sobreexpressão do 
SPRR1A no comportamento nocicetivo de animais com OA.  
 Para este efeito, um vector viral construído para expressar SPRR1A (AAV2/5-
SPRR1A) foi injetado intra-ganglionicamente em animais OA e controlo. Além disso, 
AAV2/5-GFP (de green fluorescent protein, ou proteína florescente verde) ou solução 
salina foram também injetados no DRG de outros grupos de animais. Durante as 4 
semanas seguintes o comportamento nocicetivo dos animais foi avaliado através dos 
testes de Von Frey, CatWalk e Knee-Bend, assim como a sua coordenação motora, 
usando o teste rotarod. De facto, os animais OA injetados com AAV2/5-SPRR1A 
apresentaram uma atenuação da sua nociceção e estudos de expressão génica 
confirmaram o grande aumento nos níveis de mRNA para o SPRR1A no DRG de 
animais OA e animais controlo. No entanto, uma expressão desigual de SPRR1A foi 
encontrada, com os DRG ipsilaterais dos animais controlo a revelarem uma 
sobreexpressão muito maior. Os níveis de mRNA para o ATF-3 e GFAP mostraram 
também um maior aumento nos DRG ipsilaterais dos animais controlo após injeção de 
AAV2/5-SPRR1A. Os joelhos destes animais mostraram uma ligeira erosão da 
cartilagem e consequente exposição do osso subcondral, detetada por técnicas 
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histopatológicas. Os animais injetados com AAV2/5-GFP ou solução salina 
mostraram comportamentos nocicetivos menos acentuados devido ao procedimento 
cirúrgico intra-ganglionar. No entanto, esta nociceção foi progressivamente resolvida 
após a primeira semana após a injeção. Para além disso, apesar dos animais OA 
injetados com AAV2/5-GFP ou solução salina terem mostrado comportamentos 
nocicetivos permanentes, os seus DRG ipsilaterais, assim como os dos animais 
controlo, mostraram níveis elevados de mRNA para o SPRR1A, provavelmente 
devido ao procedimento cirúrgico extremamente invasivo.  
 Os dados sugerem que o SPRR1A tem um papel importante em eventos 
periféricos que conduzem ao desenvolvimento do comportamento nocicetivo em 
modelos experimentais de OA. Alvejar a sua expressão no DRG, nomeadamente 
aumentando-a, pode ser uma potencial abordagem para atenuar a dor, possivelmente 
promovendo mecanismos regenerativos dentro dos gânglios sensitivos. No entanto, 
novos estudos ainda são necessários para avaliar os mecanismos moleculares 
subjacentes ao papel do SPRR1A e para desenvolver vias de administração menos 
invasivas para alvejar genes no DRG. 
 
Palavras-Chave: Osteoartrose (OA), Gânglios raquidianos (DRG), genes associados 
à regeneração (RAGs), pequena proteína 1A rica em prolina (SPRR1A), AAV2/5-
SPRR1A, injeção intra-ganglionar. 
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Introduction 
1.Pain         
 1.1 Pain definition 
 The pain term was subject to a lot of controversy for many years due to the 
complexity of the sensation. To overcome this disagreement, in 1994 the International 
Association for the Study of Pain (IASP), defined pain as “an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, or described 
in terms of such damage” (Merskey and Bogduk, 1994). From this definition stands 
out that pain has an individual connotation, since it combines the sensory perception 
with an unpleasant emotional experience, which demonstrates its subjectivity. While 
the sensory component allows describing the noxious stimulus in regard to the time, 
space, intensity and physical qualification, the emotional component is responsible for 
the behavioural response to pain (Walk & Poliak-Tunis, 2016). 
 Though undesirable, pain acts as a warning system, having an important 
biological function, as it is necessary for the maintenance of the body homeostasis 
(Gibson & Farrell, 2004). Nonetheless, pain often outlives its protective utility, when 
it becomes chronic, persisting after acute injury and causing alterations in the pain 
pathway.  
 1.2 Pain transmission 
 In 1906, Sherrington proposed that the detection of noxious stimuli is done by 
nociceptors (Sherrington, 1906). These are high-threshold sensory receptors of the 
peripheral nervous system (PNS) capable of transducing mechanical, chemical and 
thermal noxious stimuli from different organism locations, like skin, muscles, viscera 
and joints, into action potentials. The cell bodies of these neurons are located at 
sensory ganglia, namely trigeminal ganglia, for stimuli occurring in the face and head, 
and dorsal root ganglia (DRG) for stimuli arriving from the remaining body. Each cell 
body possesses a unique axon which bifurcates in two branches. One of the branches, 
the central, projects to the dorsal horn of the spinal cord while the peripheral branches 
terminate in many peripheral organs constituting the sensitive fibres. There are 3 
types of fibres and they are distinguished according to their diameter, myelination 
degree and conduction velocity (Aβ, Aδ and C) (Fig. 1) (Castro-Lopes & Neto, 2003). 
Aβ fibres do not contribute to acute pain, once they only detect innocuous stimuli, but 
they have the largest diameter, conduct the information faster and are myelinated. On 
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the other hand, Aδ and C fibres are responsible for transmitting the nociceptive 
information. While Aδ fibres are thinly myelinated, have medium diameter and carry 
information more rapidly, C fibres are unmyelinated, have small diameter and carry 
information very slowly. Furthermore, Aδ nociceptors are responsible for the more 
acute and rapid pain sensation, and C nociceptors for the more diffuse and prolonged 
pain (Julius & Basbaum, 2001). 
 
 
 
 
 
 
 
 
 
 
 	  	  
Figure 1. Sensitive fibres. Differences between sensitive fibres regarding to diameter, 
myelination degree and the type of the information they lead (Julius & Basbaum, 2001). 
 
In short, noxious stimuli activate the nociceptors, which in turn generate 
excitatory impulses that travel through sensory afferent axons to the dorsal horn of the 
spinal cord and from there to supraspinal sites in the central nervous system (CNS). In 
the various supraspinal regions, the information is processed, modulated and 
integrated with cardiovascular-, emotional- and cognitive-related information, 
resulting in the overall pain sensation (Fig. 2) (Bingham et al., 2009) 
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Figure 2. The nociceptive pain pathway. Activation of peripheral pain receptors 
(nociceptors) by noxious stimuli generates signals that travel through peripheral nerves to the 
cell bodies of primary afferent neurons located at sensory ganglia, such as dorsal root ganglia 
in the case of stimuli arriving from the skin or joints. From there, the action potentials are 
transmitted to the dorsal horn of spinal cord via the primary afferent neurons’ central axonal 
branch. From the dorsal horn, the inputs are carried to upper regions in the CNS through 
various ascending tracts, such as the spinothalamic tract, where they are processed and 
integrated, generating the pain sensation. Descending inhibitory and facilitatory supraspinal 
projections to the spinal cord modulate the quality of the signal that is processed at the spinal 
cord and transmitted to supraspinal regions (Bingham et al., 2009). 
 1.3 Pain Classification 
 Pain might be classified according to its duration. It may have a protective role 
and, if so, it is called acute pain. This type of pain works as an awareness alert in 
order to avoid possible damages on the organism, serving as the boost to avoid the 
source of damaging stimuli or to seek health care. Furthermore, this pain has limited 
duration since it ends when the underlying injury is solved (Cousins & Power, 1999). 
On the other hand, when pain becomes repetitive and long lasting it loses the warning 
function of physiologic nociception, and it becomes pathological itself, being called 
chronic pain (Fishman et al., 2010). According to IASP, chronic pain is defined as 
lasting for more than 6 months. Estimates suggest that 1 in 10 adults are diagnosed 
with chronic pain each year making pain a serious medical problem (Goldberg & 
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McGee, 2011). It is associated with poor quality of life and high personal, social and 
financial burden.  
 Pain can also be classified according to its cause and the place where it 
originates.  In agreement, pain is currently classified into neuropathic or nociceptive. 
According to IASP, neuropathic pain is defined as “ pain caused by a lesion or disease 
of the somatosensory system” (Merskey and Bogduk, 1994). Neuropathic pain is not a 
single disease, but a condition that may be triggered by many causes, such as diabetes, 
surgery or trauma, stroke or spinal cord injury; however, sometimes the cause is 
unknown (Jensen et al., 2011; Cooper et al., 2017). Neuropathic pain conditions are 
associated with two symptoms that stand out, namely allodynia, defined as pain 
elicited by a stimulus that normally does not cause pain, and hyperalgesia, an 
increased sensitivity to a stimulus that normally already causes pain. Contrary to 
neuropathic pain, nociceptive pain occurs with a normally functioning somatosensory 
nervous system, being defined as “pain that arises from actual or threatened damage 
to non-neural tissue and is due to the activation of nociceptors” (Nicholson, 2006). 
2. Osteoarthritis 
 2.1 Characteristics of Osteoarthritis 
 Osteoarthritis is considered the most common form of articular disease whose 
major symptom is chronic pain. It is known that the prevalence of OA increases with 
age, with notable differences between men and women, with women having higher 
rates than men. Beyond age and gender, obesity, genetic predisposition and prior joint 
injury are also risk factors for OA. Among all types of OA, knee osteoarthritis is the 
most incident (Oliveira et al., 1995) and this high prevalence has a great impact on 
physical functioning and quality of life. Therefore, identifying approaches to its 
prevention should be a public health priority (Blagojevic et al., 2010). 
 OA diseases are a result of both mechanical and biological events and are 
associated with the progressive degeneration of the articular cartilage (Forsey et al., 
2006). Articular cartilage is an avascular tissue that coats the ends of bones and has as 
prime functions to support and distribute forces during joint loading (Mow et al., 
1992). The matrix of articular cartilage is saturated with water being composed by 
chondrocytes, proteoglycans and collagen. Chondrocytes are the only cells that exist 
in the matrix and their function is to regulate the synthesis and degradation processes 
of the matrix components. Both proteoglycans and collagen are proteins and their 
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main functions are to give rigidity to the matrix and to confer tensile strength to 
cartilage, respectively (Martel-Pelletier et al., 2012).  
 OA appears when there is an imbalance between these synthesis and 
degradation activities, resulting in loss of cartilage matrix components. As 
consequence, the cartilage becomes weaker and, thus, more susceptible to mechanical 
injury leading to chondrocytes death (Goldring, 2000; Pritzker et al., 2006). 
Nevertheless, in the early stages of the disease, there are attempts by the cartilage to 
regenerate and to produce new tissue, namely fibrocartilage. Despite this, the failure 
of an adequate response of repair to injury results in irreversible changes	  (Lohmander	  et	  al.,	  1994). Although it seems that initially OA affects mainly the cartilage, the entire 
joint is involved, including the subchondral bone, ligaments, capsule, and synovial 
membrane (Martel-Pelletier et al., 2012).   
 2.2 Inflammatory component on osteoarthritic pain 
Initially, OA has been defined as a non-inflammatory disease, but features of 
inflammation have been demonstrated during OA progression. Swelling and stiffness 
of the joint, synovitis (inflammation of the synovium), increases in the number of 
cytokines and in the number of immune cells are some of the inflammatory 
characteristics associated with OA (Goldring & Otero, 2011), as shown in Fig.3. Joint 
swelling and stiffness are clinical signs observed in OA patients reflecting the 
presence of synovitis, which is characterized by hyperplasia of the synovium and by 
an infiltration of T and B lymphocytes (Scanzello & Goldring, 2012). Additionally, 
the dysfunctionality of chondrocytes, which characterizes this disease, results in the 
production of inflammatory mediators, and of pro-inflammatory cartilage degradation 
products that perpetuate the inflammatory response. Cytokines, including interleukins 
1 (IL-1), 6 (IL-6) and 17 (IL-17), and tumour necrosis factor alpha (TNF-α), are some 
of the inflammatory mediators that can be identified in the synovial fluid, cartilage 
and synovium of OA patients (Scanzello et al., 2009; Martel-Pelletier et al., 2016). 
Thus, the inflammation suggested by these clinic signs might contribute to the 
pathogenesis of OA, and explain some of the OA symptomatology, namely the pain-
associated to this condition. 
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Figure 3. Inflammatory process in OA. Cytokine production (IL-1β, TNF-α and IL-6) and 
synovitis demonstrated by infiltration of T and B lymphocytes, and macrophages are involved 
in the inflammatory process of OA (Chevalier et al., 2013). Abbreviations: MMP, matrix 
metalloproteinase; RANKL, receptor activator of nuclear factor κB ligand, also known as 
tumor necrosis factor ligand superfamily member 11; TGF-β, transforming growth factor β; 
IL-1B, interleukin1 beta; IL-6, interleukin 6; TNF, tumor necrosis factor. 
 2.3 Neuropathic and nociceptive components on osteoarthritic pain 
 During inflammation the peripheral nerve terminals are sensitized by 
inflammatory mediators, involving changes in joint nociceptors. For this reason, 
osteoarthritic pain has for long been considered as nociceptive pain (Schaible et al., 
2009). However, several studies suggested the presence of a non-nociceptive pain 
component associated with abnormally excitable pain pathways in the peripheral and 
the central nervous systems (Valdes et al., 2014). Thus, the presence of 
somatosensory abnormalities, like mechanical and thermal hyperalgesia, allodynia 
and referred pain, contributed to the notion that neuropathic pain mechanisms might 
be involved in osteoarthritic pain. These characteristics may be useful in the clinical 
assessment to distinguish neuropathic pain from nociceptive pain and for this, 
screening questionnaires, such as PainDETECT are used. Through the use of this 
questionnaire in one cohort of patients with knee OA, 34% revealed signs of 
neuropathy, including burning, tingling or numbness (Hochman et al., 2013; Valdes et 
al., 2014). Apart from the clinical evidences, several experimental studies 
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demonstrated there is an increase of markers of nerve injury in sensory nerves 
innervating the knee of OA rats. Indeed, it was shown that activating transcription 
factor 3 (ATF-3) and neuropeptide Y (NPY), both markers of neuronal injury, are 
highly expressed in DRG neurons after OA induction by MIA (Ivanavicius et al., 
2007; Ferreira-Gomes et al., 2012b) and collagenase (Adaes et al., 2015). These 
molecular evidences corroborate the involvement of neuropathic pain events in OA, 
suggesting that OA pain may come from both nociceptive- and neuropathic-like 
mechanisms. 
3. Osteoarthritic Knee Pain 
 3.1 Osteoarthritic pain source 
 The main sensation attributed to the joint is pain, being extremely difficult to 
understand its source. However, as the cartilage is avascular and aneural, damaged 
cartilage cannot generate pain directly (Felson, 1990). Therefore, pain must be arising 
from other structures that are richly enervated such as the subchondral bone, 
periosteum, periarticular ligaments, periarticular muscles, synovium and joint capsule 
(Salaffi et al., 2014), as shown in Fig. 4. 
 In order to evaluate all structures in a joint and identify structural 
abnormalities, and possibly correlate them with OA pain, magnetic resonance 
imaging (MRI) might be used. In this regard, subchondral microfratures, bone 
stretching with lifting of the periosteum due to the formation of osteophytes, joint 
capsule distension and synovial inflammation are some of the causes proposed as 
sources of pain in OA (Felson et al., 2001; Schaible, 2012). It has also been shown 
that anatomical changes such as bone marrow lesions (BML) (Felson et al., 2001), 
sub-articular bone attrition (Hill et al., 2001), synovitis, and effusion (Hill et al., 
2001; Hill et al., 2007) are related to knee pain. Indeed, Felson et al showed a high 
incidence of bone marrow edema (BME) in 78% of patients with OA knee pain 
against 30% of non-painful knee OA patients (Schaible, 2012). Furthermore, similar 
results were found regarding articular lesions, knee effusions and synovitis, since 
these features have been most frequently found in patients with knee pain than in 
patients with knee OA but without pain (Hill et al., 2001; Hill et al., 2007) 
 It has been suggested that the growth of new blood vessels, or angiogenesis, 
may contribute to OA pain (Ashraf & Walsh, 2008). During the course of OA there is 
the formation of new cartilage that is invaded by newly formed blood vessels with the 
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presence of sensory nerves. These nerve terminals mediate a sustained burning pain 
commonly described by patients with OA (Ashraf & Walsh, 2008). Furthermore, 
other OA features, such as articular cartilage loss, synovial inflammation, fibrosis, 
subchondral bone remodelling and osteophyte formation, may be perpetuated by 
angiogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Innervation of a typical articular joint. Tissues such as subchondral bone, joint 
capsule and synovium receive afferent innervations including C and Aδ fibres (Staunton et 
al., 2013) 
 3.2 Innervation on the joint 
 The knee joint is richly innervated by both sensory and sympathetic peripheral 
nerve fibres, of which about 80% are unmyelinated. The major function of sensory 
nerves is to detect and convey mechanical information from the joint to the CNS. 
Sensory thick myelinated Aβ fibres are thought to transmit information about 
movement and position of the joint and about pressure exerted on articular tissues. 
However, knee joints are mostly innervated by nociceptive afferent nerve fibres, 
namely thinly myelinated Aδ-fibres and unmyelinated C-fibres. Sensory thick 
myelinated Aβ fibres are equipped with corpuscular Ruffini-, Golgi- and Pacini- type 
endings and they are found in ligaments, fibrous capsule, menisc and adjacent 
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periosteum, while thinly myelinated Aδ-fibres and unmyelinated C-fibres terminate as 
free nerve endings in the same sites of thick myelinated fibres and also in the adipose 
tissue (Schaible & Grubb, 1993).  
 Articular afferents have been classified into different groups according to their 
electrophysiological characteristics. Thick myelinated fibres are activated by 
innocuous movements, such as by touch, making them low threshold fibres. C- and 
Aδ-fibres have a higher mechanical threshold and are often activated by noxious 
manipulations, as, flexion and/or extension and rotations of the joint beyond the 
normal working range (Schaible & Grubb, 1993; Scaible	  &	  Schmidt,	  1983).  
 In sum, two types of sensory fibres innervate knee joints, the high-threshold 
fibres that may be considered as nociceptive units since they lead to pain sensations, 
and the low threshold fibres that are considered proprioceptive (Schaible & Grubb, 
1993). 
 3.3 Sensory neurons 
 The cell bodies of the primary sensory neurons with fibres innervating the 
joints are located in the PNS, namely in the DRGs. Besides sensory neurons, which 
are pseudounipolar and innervate several structures, the DRGs contain other cell types 
such as glial cells, endothelial cells and macrophages (Berta et al., 2017). Glial cells 
might be of two types, Schwann cells, and satellite glial cells (SGCs). Schwann cells 
might be myelinating, wrapping around the axons of motor and sensory neurons to 
form the myelin sheath, or non-myelinating, while SGCs surround the cell bodies and 
proximal part of the axon forming with the sensory neuron an anatomical and 
functional neuron-SGC unit. SGCs in sensory ganglia might be visualized by 
immunolabelling with glutamine synthase, which they produce in basal conditions, 
and glial fibrillary acidic protein (GFAP) whose expression is upregulated when these 
cells become activated by stressful or damaging environments to the ganglia or to the 
sensory neurons, including inflammation and peripheral nerve injury (Hanani, 2005). 
The primary sensory neurons in DRGs are categorized into different 
populations with distinct characteristics in what concerns the size of their cell bodies, 
the stimuli they are sensitive to, and their neurochemistry. The C nociceptors usually 
have the smaller cell size and most are polymodal, that is, are sensitive to mechanical, 
chemical and thermal stimuli. However, there are some of them that are sensitive to 
thermal and chemical stimuli (mechano-insensitive nociceptors), others that are 
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sensitive only to chemical stimuli and still others that are sensitive only to thermal 
stimuli (Belmonte & Cervero, 1996). Beyond this, C nociceptors are referred to as silent 
nociceptors when they only respond to stimuli in the presence of an injury (Schmidt et 
al., 1995). Concerning the Aδ nociceptors, they are usually of medium cell size and 
there are two main classes. Type I respond to both mechanical and chemical stimuli, 
and despite having high heat thresholds, if the heat stimulus is maintained, these 
afferents became sensitized and respond at lower temperatures. Type II Aδ 
nociceptors respond predominantly to thermal stimuli and have a very high 
mechanical threshold (Basbaum et al., 2009). Regarding the neurochemistry, 
nociceptors are once again divided into groups. Glutamate is the predominant 
excitatory neurotransmitter in all nociceptors. C-fiber nociceptors are then separated 
into two subtypes, peptidergic and non-peptidergic. The peptidergic type have the 
ability to produce neuropeptides like substance P (SP) and calcitonin gene-related 
peptide (CGRP), and express TrkA neurotrophin receptor, which responds to neuronal 
growth factor (NGF) (Belmonte & Cervero, 1996). The non-peptidergic type can be 
identified by the presence of enzymes (FRAP-Fluoride-resistant acid phosphatase) 
and binding sites for the isolectin-B4 (Belmonte & Cervero, 1996). Finally, Aδ 
nociceptors are identified by the presence of certain filaments, such as neurofilament 
protein (NF200) (Belmonte & Cervero, 1996). 
CGRP and SP have been shown to be expressed in joint afferents (O'Brien et 
al., 1989). In the MIA model of OA, an increased expression of SP and CGRP has 
been found in neurons innervating the knee joint (Ahmed et al., 2012). Furthermore, 
since these neurotransmitters migrate to nerve terminals of primary afferent neurons, 
SP and CGRP were found increased as well in the synovium in a rat anterior cruciate 
ligament transection model of OA (Yoshida et al., 2012). So, this marked increase in 
the production of neuropeptides after OA development may be involved in joint pain 
processing. Through retrograde labeling with fluorogold injected into the knee it has 
been reported that non-peptidergic nerve fibres (IB4-positive) are present at very low 
levels in the rat knee joint of control rats and this was not significantly different from 
the percentage found in rats with OA induced by MIA (Ferreira-Gomes et al., 2010). 
Similarly, in the same study, it was found a large percentage of NF-200 positive 
backlabeled cells in the DRGs neurons innervating the knee joint with no differences 
between control and OA rats (Ferreira-Gomes et al., 2010). 
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 In non-physiological conditions, for example in inflammatory or neuropathic 
pain models, neurochemical and anatomical changes can occur in Aβ neurons. In 
these conditions Aβ neurons begin to synthesize substances involved in pain sensation 
which may lead to their hypersensitization and to the acquired ability of being 
activated by higher threshold stimuli they would normally not transduce. In rats with 
OA, Ferreira-Gomes et al showed for the first time the alteration of the cell size 
distribution pattern of CGRP-positive neurons, where large cells started to express 
CGRP, suggesting a phenotypic switch of these cells has occurred to assume the 
characteristics of nociceptors (Ferreira-Gomes et al., 2010). 
 3.4 Treatments available for osteoarthritic pain  
 Current management of OA pain remains unsatisfactory for many patients, 
both in terms of providing pain relief, and in terms of producing undesirable side 
effects (Malfait & Schnitzer, 2013). Different types of interventions are used in an 
attempt for pain control and current treatment guidelines recommend the use of 
opioids, non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol and intra-
articular therapy with glucocorticoid and hyaluronan preparations (Rhon, 2008; 
Malfait & Schnitzer, 2013). Some patients show pain relief and increased joint 
function, but also several side effects. Problems on gastrointestinal, renal, hepatic and 
cardiovascular systems are some of the complications associated with these therapies 
(Watson et al., 2000; Crofford, 2013). There are, however, a number of patients, 
where current drug regimens fail to achieve efficacy, which justifies the necessity to 
develop new therapies targeting the nociceptive and neuropathic pain mechanisms 
involved.  
4. Experimental osteoarthritis  
 4.1 Animal models in Osteoarthritis  
 The lack of an effective OA treatment reflects the need for a better 
understanding of the pathophysiology and aetiopathology of this joint disease. 
However, since human clinical studies present several limitations and difficulties, the 
use of animal models became extremely important (Abramson & Attur, 2009; Vincent 
et al., 2012). Although there are several OA animal models, there is still no one that is 
ideal, as they should mimic as much as possible the different complex features 
observed in OA patients (Abramson & Attur, 2009). Limitations are mostly due to 
differences in anatomy, dimensions, biomechanics, cartilage repair processes and 
FMUP      
     Effect of SPRR1A overexpression on the nociceptive behaviour of OA animals 
     	  
12	   	  
cartilage thickness between animal and human joints. Therefore, as each model 
mimics different OA features, it is necessary the use of several to cover the full range 
of alterations that characterize OA.  
 The majority of animal model studies focus on elucidating mechanisms 
underlying damage to joint structures, while the study of OA pain was, for many 
years, forgotten (Brandt, 2002). However, more recent studies have been focusing on 
the development of animal models that best mimic OA pain (Havelin et al., 2016; 
Otis et al., 2016). OA models can be spontaneous (naturally occurring), genetically 
modified or chemically- and surgically-induced (Tables 1); yet, chemical-induced 
models are the most used in OA pain studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
FMUP      
     Effect of SPRR1A overexpression on the nociceptive behaviour of OA animals 
     	  
13	  	  
Table 1. Animal models used in the OA pain study. Adapted from Little & Zaki, 2012 and 
from Lampropoulou-Adamidou et al, 2014. Key: HL -hind limb, VF-Von frey filaments, EP -
electrophysiological recordings from knee joint afferents, PAM-pressure application 
measurement device, ROM-range of motion analysis, VRA-videoradiographic analysis, DPA-
dynamic plantar aesthesiometer (automated VF), LABORAS- laboratory animal behavior 
observation registration and analysis system, MIA-monoiodoacetate induced arthritis, ACLT-
anterior cruciate ligament transection, MCLT- medial collateral ligament transection, MMT- 
medial meniscal transection, MM- medial meniscectomy, DMM- destabilization of the medial 
meniscus, IA OC fragment- intra-articular osteochondral fragment. 
  Animal models Species Outcome measures 
Spontaneous    
Age-associated   Guinea pig Mechanosensitivity (EP) 
 
Obesity 
  
Mouse 
Grip strength meter, motor coordination (rotarod), gait 
analysis, spontaneous locomotor activity 
    
Genetic modification  
 IL1B over expression                                           
Rat  
 
Thermal hyperalgesia, mechanical allodynia (VF), gait 
analysis (CatWalk), foot printing, HL weight distribution, 
treadmill 
Col9a1 (_/_) 
 
 Mouse Motor coordination (rotarod), gait analysis, mechanical 
allodynia (VF), thermal hyperalgesia (hotplate, tail flick), grip 
strength 
Intra-articular injections  
(Chemical models)  
   
MIA  Rat, mouse Grip strength meter, thermal hyperalgesia, mechanical 
hyperalgesia, HL weight distribution (incapacitance), 
mechanical allodynia (VF), mechanosensitivity (EP), gait 
analysis (CatWalk), movement-induced nociception (Knee-
Bend), movement and loading-induced nociception (CatWalk) 
 
Na Urate 
  
Cat, Parrot 
 
Weight distribution, subjective pain scores                                            
AIA  Mouse, Rat HL weight distribution (incapacitance), mechanical allodynia 
(VF), 1ºmechanical hyperalgesia (PAM), 2º mechanical 
hyperalgesia (DPA), range of motion (VRA), gait analysis  
Adjuvant  Rabbit, Rat 
 
HL weight distribution; Mechanical hyperalgesia (VF)  
Carrageenan/Kaolin 
 
 
 Mouse, Guinea pig, 
rat 
Thermal hyperalgesia (Hargreaves & hotplate) 
Collagenase (enzymatic)  Mouse, Rat (Adaes 
et al., 2014; Adaes 
et al., 2015) 
Visual gait analysis (treadmill), joint tenderness (palpometer), 
movement-induced nociception (Knee-Bend), movement and 
loading-induced nociception (CatWalk) 
 
 
Surgical    
ACLT           Rat, Dog, Rabbit           Gait analysis 
MCLT                                             Rat       HL weight distribution (incapacitance) 
MMT, MM (unilateral)                               Rat, Sheep                 HL weight distribution (incapacitance), mechanical allodynia 
(VF) 
MM (bilateral)                                  Sheep    Ground reaction force 
MM (partial)                                    Rabbit, Rat, Mouse HL weight distribution(incapacitance), tactile allodynia (VF) 
DMM    Mouse                 HL weight distribution (incapacitance), mechanical allodynia 
(VF), thermal hyperalgesia, locomotor activity (LABORAS) 
IA OC fragment    Horse                             Clinical observation of lameness 
ACLT& partial MM  Rat, Guinea pig         Gait analysis (CatWalk), mechanical allodynia (VF) 
 
ACLT//MMT/MCLT                            Rat Rotarod 
MCLT & MMT  Rat Mechanical allodynia (VF), thermal hyperalgesia (Hargreaves 
apparatus), HL weight distribution (incapacitance), 
mechanical hyperalgesia (paw pressure device) 
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 4.2 Collagenase model of Osteoarthritis 
 The collagenase-induced OA model belongs to the chemical induced models 
group and is based on joint-instability induction through intra-articular collagenase 
injection, being predominantly used to study mechanisms underlying structural joint 
damage (Blom et al., 2004). Collagenase damages the structures that contain collagen 
type I, such as tendons and ligaments, leading to alterations of the joints. 
Histopathological alterations of the knee joint similar to those observed in human OA 
have been described after collagenase injection in rats (Al-Safar et al., 2009; Adaes et 
al., 2014) and mice (Blom et al., 2004; Blom et al., 2007), such as thinning of 
articular cartilage, cartilage matrix loss, loss of chondrocyte clustering, loss of 
proteoglycan staining and exposure of the subchondral bone (Adaes et al., 2014).  There are evidences that the temporal pattern of these changes directly correlates with 
the time of OA development elapsed following its induction by collagenase injection 
(Al-Safar et al., 2009; Adaes et al., 2014).  
Articular cartilage is not the only structure affected by collagenase; the 
subchondral bone and synovial membrane are also targets of modifications. Indeed, 
upon damage of the cartilage, the subchondral bone slowly becomes exposed to an 
harmful environment and an (almost) bone-to-bone friction leads to bone fissures that 
has also been described in the collagenase model (Adaes et al., 2014). Moreover, a 
moderate inflammatory reaction was described in the mice (van der Kraan et al., 
1989) and rats’ (Adaes et al., 2014) knees in the initial phase of OA, as indicated by 
synovial infiltration with inflammatory cells and joint swelling, portraying the 
inflammatory response observed in OA humans. Thus, these modifications reproduce 
some of the main features associated with OA progression in humans. 
 These findings suggested that the intra-articular injection of collagenase is a 
promising alternative to study OA-associated pain. For that reason, our group recently 
investigated if the intra-articular collagenase injection in the rat knee could be a good 
model to study OA-associated nociception in rats. Thus, during 6 weeks, nociception 
induced by movement and loading on the affected joint was evaluated in the animals 
by the Knee-Bend and CatWalk tests. The results demonstrated significant differences 
between OA and control animals with an increase in the ipsi-contra ratio for the 
Knee-Bend score in OA animals, and a reduction in the ipsilateral paw print intensity 
of OA animals, until the sixth week. Therefore, for the first time, it was demonstrated 
that rats displaying OA structural features induced by collagenase injection in the 
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knee, also showed nociceptive behaviour associated with movement and loading on 
the OA joint, which represent patients´ major complaints (Adaes et al., 2014). 
5. Regeneration associated with osteoarthritis  
 5.1 Regeneration associated genes after PNI (peripheral nerve injury) 
 Neurons injured in the adult mammalian CNS normally fail to regenerate. In 
contrast, following injury to the PNS neurons reveal robust regenerative response 
(Harel & Strittmatter, 2006; Starkey et al., 2009). However, the molecular 
mechanisms underlying successful nerve regeneration in the PNS remains to be 
clarified. 
 For the success of nerve regeneration is essential an intrinsic growth ability 
and an extrinsic permissive environment. The intrinsic growth refers to the ability of 
injured neurons to coordinate the expression of some genes that probably assist rapid 
regeneration, called regeneration-associated genes (RAGs) (Raivich & Makwana, 
2007). This intrinsic growth depends on the existence of a permissive environment 
that is favorable for the axonal regrowth of surviving neurons. Schwann cells and 
macrophages are part of this environment and they are at the injury site to phagocyte 
the degenerative products. Beyond them, astrocytes and microglia complete this 
environment by surrounding the cell bodies (Leon et al., 2000; Moran & Graeber, 
2004). Once Schwann cells and macrophages are active in the injury site they 
synthesize a cocktail of neurotrophic factors such as nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), and cytokines. 
Consequently, begins the activation of an intrinsic growth program that includes the 
production of some proteins involved in regeneration. It is known that sensory 
neurons of the DRG are the most favorable neuronal population to address 
interactions between peripheral regenerative mechanisms and CNS growth and 
therefore, the expression of many RAGs has been studied in this population after 
situations of peripheral lesion (Snider et al., 2002).  
 Activating transcription factor 3 (ATF-3) is, as previously stated, known as an 
injury marker in the nervous system, but, actually ATF-3 overexpression revealed 
pro-regenerative and neuroprotective functions not only improving regeneration of 
peripheral and central DRG branches but also causing neurite growth (Seijffers et al., 
2007; Fagoe et al., 2015). Growth associated protein (GAP-43) is a regeneration-
associated protein which was shown to be increased in DRG neurons after induction 
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of OA by MIA (Ferreira-Gomes et al., 2012b), and is an important regulator of 
growth cone motility during nervous system development (Snider et al., 2002). Small 
proline rich protein 1A (SPRR1A) was also associated to regeneration having been 
detected during successful sciatic nerve regeneration in the mouse. However, unlike 
GAP-43, SPRR1A is not expressed during development or in naïve adult tissue 
(Bonilla et al., 2002). SRY-BOX11 transcription factor (SOX11) is expressed during 
the developing nervous system and it has been shown to have an important role in 
axon growth (Jankowski et al., 2009). TRAF family member-associated NF-Kappa B 
activator (TANK) is another molecule that is increased in response to peripheral nerve 
injury and, furthermore, it has been reported that its expression is regulated by SOX11 
(Salerno et al., 2013). The brain-soluble protein BASP1 belongs to the family of 
growth-associated proteins, which also includes GAP-43, and is expressed in several 
tissues (Carpenter et al., 2004), but more abundantly in neurons throughout brain 
development. BASP1 expression is increased during nerve regeneration and in adult 
neurons its overexpression promotes sprouting (Korshunova et al., 2008). Although 
they belong to the same family, BASP1 appears later in development than GAP-43 
(Console-Bram et al., 1996). 
 Hereupon, our group hypothesized that the neuronal injury observed in DRG 
neurons innervating OA joints, indicated by the expression of ATF-3 and also NPY 
(Ferreira-Gomes et al., 2012b), could induce a regeneration response reflected in an 
upregulation of some of these molecules. In fact, the increased expression of one of 
these molecules, GAP-43, had already been shown by our group in DRG neurons of 
MIA-induced OA rats (Ferreira-Gomes et al., 2012b), as already mentioned. Thus, in 
the collagenase model, the expression of some RAGs, including SPRR1A, SOX11, 
TANK and BASP1, was evaluated in sensory neurons innervating OA joints. It was 
found by RT-PCR analysis that Sox11 and Sprr1a mRNA expression was induced 
during OA in DRG neurons, while Tank and Basp1 levels remained unaffected. 
Nonetheless, the most marked changes were observed in the expression of the Sprr1a 
gene. Western Blot analysis confirmed the previous result showing an increased 
expression of SPRR1A in the ipsilateral DRG of collagenase injected rats. Through 
immunohistochemical experiments, our group evaluated as well the cellular 
localization of the SPRR1A protein. Data in the DRG of OA rats was consistent with 
a pattern of SPRR1A staining in neuronal cell bodies and axonal processes. In 
addition, double immunolabelling for SPRR1A and ATF-3 showed a higher 
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percentage of co-localization in OA animals comparing with the control animals, 
suggesting that during OA SPRR1A is preferentially expressed in injured neurons. 
These results may indicate that the regenerative process associated with lesion of 
nerve terminals may play a role in nociception associated with OA (Adães et al., 
unpublished data). 
 5.2 Small proline rich protein 1A (SPRR1A) 
 The human SPRR genes consist of two SPRR1 genes (SPRR1A and 1B), 
seven SPRR2 genes (SPRR2A, 2B, 2C, 2D, 2E, 2F and 2G) and a single SPRR3 
gene. All three members encode small proteins that are rich in proline and are built up 
from repeating elements (Gibbs et al., 1993). In 1988, the proteins belonging to this 
class were identified for the first time as major components of the cross-linked 
cornified envelop of skin keratinocytes and from this moment, the multigene SPRR 
family became part of the keratinocyte differentiation markers (Kartasova et al., 
1988). A few years later, SPRR1A was proposed as a new regeneration associated 
gene since it was highly expressed in DRG neurons after peripheral nerve injury and 
during sciatic nerve regeneration (Bonilla et al., 2002; Jankowski et al., 2009). Thus, 
it seems that SPRR1A induction is related with a regenerative capacity, being highly 
expressed in the cell bodies and central terminals of primary sensory neurons 
following peripheral nerve injury. However, at the time, a detailed characterization of 
SPRR1A expression had not been made, and it was extremely important to realize 
which DRG subpopulations express SPRR1A. Co-expression of SPRR1A with 
specific DRG subpopulations markers showed that there is a co-localization of 
SPRR1A with CGRP, IB4 and NF200, revealing that all three subpopulations express 
SPRR1A (Starkey et al., 2009).  
 A possible mechanism of SPRR1A expression involves the RAG Sox11.	  
SOX11 proteins have an important role in cell fate, survival and differentiation across 
all developing organ systems (Lefebvre et al., 2007) and their dysfunction probably is 
related with several diseases. The expression of this molecule in DRG increased the 
axonal growth rate after crush injury; however, SPRR1A seems to be indispensable 
for the effect of SOX11, since SPRR1A knockdown significantly reduced the 
stimulatory effect of SOX11 on neurite outgrowth. On the other hand, the SOX11 
expression in DRG neurons driven by the herpes simplex virus conjugated with the 
Sox11 gene (HSV-SOX11) caused a significant increase in SPRR1A expression. 
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These data suggest that the transcriptional activation of SPRR1A by SOX11 is a 
critical step in nerve regeneration (Jing et al., 2012). Results obtained by our group go 
in line with this, since after OA induction there was an increase of both genes (Adães 
et al., unpublished data). Additionally, there seems to be an interaction between ATF-
3 and SOX11 because ATF-3 expression was reduced in response to SOX11 
knockdown (Jankowski et al., 2009). Curiously, the inverse was not found, i.e., ATF-
3 knockdown had no effect on SOX11 level (Jankowski et al., 2009). This suggests 
that SOX11 may influence the regulation of ATF-3 gene expression. As above 
mentioned, our group observed very high levels of co-expression of SPRR1A and 
ATF-3 in the collagenase OA model which suggest that SOX11, ATF-3 and SPRR1A 
are probably part of the same regeneration-inducing signaling pathway (Adães et al., 
unpublished data). Thus, it is possible that SOX11 is upregulated in response to injury 
of sensory nerve endings associated with OA, which may induce the expression of 
ATF-3 and SPRR1A, among other RAGs, to initiate the regenerative process.  
6. An approach to gene delivery  
 6.1 Adeno-associated virus (AAV) as vectors 
 Vector choice plays a crucial role for the success of gene therapy and several 
considerations must be taken into account, like the capacity to attach to and enter the 
target cell, to be successfully transferred to the nucleus, the ability to be expressed in 
the nucleus for a continued period of time and the lack of toxicity (Daya & Berns, 
2008). Presently, the most successful gene therapy strategies are related to 
recombinant viral vectors (e.g., adeno-associated virus, adenovirus, lentivirus, 
retrovirus, and herpes simplex virus) (Yu et al., 2016). Adeno-associated virus (AAV) 
has been one of the most widely used vector systems for gene therapy because of its 
lack of pathogenicity, its persistence, its low immunogenicity, the existence of several 
serotypes and its broad cellular tropism (Daya & Berns, 2008). AAV is a non-
enveloped parvovirus that requires the presence of a helper virus for efficient 
replication (Buller et al., 1981). The wild-type AAV genome consists of a linear 
single-stranded DNA molecule with approximately 4.7 kilobases that includes two 
open reading frames, Rep and Cap, flanked by inverted terminals repeats 
(ITRs)(Koczot et al., 1973). ITRs are necessary for replication and packaging so, for 
gene delivery the transgene is placed between the two ITRs, and Rep and Cap are 
supplied in trans. Following molecular transduction of target cells the rAAV 
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(recombinant adeno-associated virus) genome must be converted to double-stranded 
transcriptionally active forms to facilitate transgene expression (Weitzman & Linden, 
2011).  
 Several serotypes of AAV vectors have been identified and they are used to 
direct transgene expression in a variety of tissues, including the nervous system, but 
most studies for gene therapy are based on the AAV serotype 2. The AAV2 vector 
genome can be crossed-packaged with capsids from different AAV serotypes 
resulting in increased neural tropism and spread of the viral transgene (Rabinowitz et 
al., 2002).  
 6.2 Intra-ganglionic injection - DRG as a target for gene delivery 
 Several studies have shown that gene therapy targeting the PNS can be an 
approach for chronic pain treatment (Handy et al., 2011; Goins et al., 2012). It is 
known that after a peripheral injury several cellular mechanisms are altered and this 
disturbance resides in diverse sites, including in the soma of the injured sensory 
neurons. DRG contain the cell bodies of these neurons and therefore are an ideal 
target for therapeutic gene transfer (Yu et al., 2016). Accordingly, gene transfer to 
sensory neurons within the nociceptive pathway is a new tool to study pain. Lately, 
the rAAV vector system has received a sudden attention for in vivo viral gene transfer 
to the DRG neurons in various animal models of chronic pain. For example, intra-
ganglionic injection of AAV2/8 carrying the recombinant gene for serine protease 
inhibitor 3 attenuated neuropathic pain after spared nerve injury (Vicuna et al., 2015). 
In another study, similar results were obtained after intra-ganglionic injection of an 
AAV2/5 carrying a gene for short hairpin RNA targeting the Nav1.3 channel (Samad 
et al., 2013). Recently, the AAV2/5 serotype showed an efficient transduction rate in 
DRG neurons, including small peptidergic neurons and small non-peptidergic neurons 
(Mason et al., 2010). 
Another type of approaches can be done in order to target the DRG. Thus, 
intrathecal delivery of AAV produces effective gene transfer to the DRG and spinal 
cord (Federici et al., 2012; Fagoe et al., 2014); however, this type of methodology 
requires far more AAV vector, making it a more expensive method compared to the 
intra-ganglionic injection (Fagoe et al., 2014). Furthermore, due to propagation of the 
vectors into the cerebrospinal fluid (CSF) there is also a robust transduction in several 
spinal cord tissues including spinal motor neurons (Federici et al., 2012). Thus, AAV 
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intrathecal administration may be more effective in neurological disease processes 
that require gene delivery to motor neurons (Federici et al., 2012). Intraneural 
injections into the sciatic nerve are another route of AAV delivery, but despite it can 
transfer genes to primary sensory neurons, the transduction of motor neurons is 
preponderant (Boulis et al., 2003). Intramuscular AAV injection does not show 
efficiency in transducing sensory neurons (Towne et al., 2009), unlike intraperitoneal 
AAV injections (Machida et al., 2013).   
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Objectives 
 Acknowledging our previous results where an upregulation of SPRR1A was 
observed after OA induction by intra-articular collagenase injection, we aimed at 
better understanding the SPRR1A role in this pathology, as well as its potential role as 
a treatment target, by upregulating its expression in DRGs, through gene delivery, and 
evaluating its effects on the nociceptive behavior. For that purpose, the following 
objectives were pursued: 
 
o To ascertain the efficiency of the intra-ganglionic AAV injection – To 
achieve this goal we performed the intra-ganglionic injection of a 
recombinant adeno-associated virus (rAAV) engineered to express green 
fluorescent protein (GFP) as a reporter gene, in DRG of naïve rats. To assure 
the best efficiency, different end-points of viral transduction were studied (4, 
6 and 8 weeks after intra-ganglionic surgery), by using 
immunohistochemistry against GFP to quantify the percentage of sensory 
neurons expressing GFP.  
o To evaluate which type of cells are transfected by the AAV - By double 
immunohistochemistry we analyzed the co-localization between GFP and 
GFAP (a marker of Satellite glial cells) in DRGs neurons from naïve animals 
injected with AAV-GFP. 
o To evaluate the effect of SPRR1A overexpression on the nociceptive 
behavior of controls and OA animals – To achieve this, the intra-ganglionic 
injection of either rAAV-GFP or rAAV-SPRR1A was performed in both OA 
and control animals and their nociceptive behavior was evaluated by using the 
CatWalk, Von Frey, Knee-Bend and Rota-rod tests. An additional group of 
control and OA animals received an intra-ganglionic injection of saline. 
o To evaluate SPRR1A expression in control and OA animals injected with 
rAAV-GFP, rAAV-SPRR1A or saline – To achieve this, the SPRR1A gene 
expression was evaluated in DRGs by real-time quantitative PCR.  
o To evaluate expression of other markers of neuronal damage/ regeneration in 
OA and control animals injected with rAAV-SPRR1A- In order to achieve 
this goal, the expression of ATF-3 was quantified in DRGs by real-time 
quantitative PCR, as well as that of GFAP, considered a marker of SGCs 
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increased activation.   
o To evaluate the extent of the histopathological lesions of knee joint sections - 
By staining knee sections by the Fast Green and Safranin O histological 
method, the pathological changes in the knee joints of OA animals following 
intra-ganglionic injections of AAV-SPRR1A, AAV-GFP or saline were 
assessed.  
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Materials and Methods 
1. Animal Handling 
 Experiments were carried out in adult male Wistar rats weighting between 175 
and 225g at the beginning of the investigation. The 43 rats used were housed in 
Biotério Geral do Centro de Investigação Médica da Faculdade de Medicina da 
Universidade do Porto, two per cage with water and food ad libitum, under controlled 
conditions of temperature and humidity, 22±2ºC and 55±5%, respectively. In 
addition, the lighting conditions were also controlled (12-hour light/12-hour dark 
cycle). 
 Of all the animals used in this research, 14 were from Biotério Geral do 
Centro de Investigação Médica da Faculdade de Medicina da Universidade do Porto, 
while the remaining 29 animals were from Charles River (France). Animals from 
Charles River required a period of adaptation to the animal facility conditions of 5 
days. After this period, all the animals went through a phase of 4 days of habituation 
to manipulation by the researcher as well as to the behavioural nociceptive tests. 
During all the period of the research procedures, the health state of the animals was 
ascertained, with particular attention to weight loss, loss of mobility, bad healing, 
opening of stitches and self-mutilation.  
All the experimental procedures were performed according to the ethical 
norms for the study of experimental pain in conscious animals (Zimmermann, 1983), 
as well as the regulations of local authorities on the use of animals for scientific 
purposes. 
2. Induction of osteoarthritis - Intra-articular injection of 
Collagenase 
To induce osteoarthritis in the animals, an intra-articular injection of 500 U of 
type II collagenase (ColII, Sigma-aldrich, St. Louis- USA) was performed under a 
brief isoflurane anaesthesia (5% for induction, 2.5% for maintenance). Intra-articular 
injections were performed using a Hamilton syringe with a 26 G needle inserted 
through the patellar ligament into the right knee joint cavity. Animals received two 
injections, separated by three days, of 25 µL of either saline (control group) or 500U 
of ColII from Clostridium histolyticum dissolved in saline and filtered thought a 0.22 
µm membrane (OA group), as previously described (Adaes et al., 2014). 
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3. Construction of viral vectors 
 Viral vectors containing humanized GFP and SPRR1A were a gift from Jack 
Kanaan and Nick Lipton from the University of Michigan, USA. Briefly, GFP and 
SPRR1A genes were inserted into an adeno-associated virus plasmid backbone. 
Expression of the transgenes was driven by the chicken beta actin/cytomegalovirus 
enhancer (CβA/CMV) promoter hybrid. The vectors contained AAV2 inverted 
terminal repeats (ITRs) and were packaged into AAV5 capsids via co-transfection 
with a plasmid containing rep and cap genes and adenovirus helper functions. Thus, 
two adeno-associated virus constructed in the same way served as vectors to GFP 
(AAV2/5-GFP) and SPRR1A (AAV2/5-SPRR1A) (Polinski et al., 2015). The vectors 
titer used in this study was 5.88x1013 genomes/mL. With the aim of preserve the viral 
stability and titer, viral preparations were stored at 4ºC. Additionally, syringes, 
pipettes and microcentrifuge tubes which contacted the viruses were first coated in 
SigmaCote ® (Sigma-Aldrich, St. Louis, USA) to minimize binding of viral particles 
(Polinski et al., 2015). 
4. Intra-ganglionic injections of rAAV 2/5-SPRR1A, rAAV2/5-GFP 
and saline 
 Fourteen days after intra-articular injections of ColII or saline, animals were 
submitted to an intra-ganglionic injection of rAAV2/5-SPRR1A, rAAV2/5-GFP or 
saline. After intraperitoneal anaesthesia with Medetomidine hydrochloride (0.5mg/kg, 
Domitor , Esteve Farma, Carnaxide-Portugal) and ketamine hydrochloride 
(75mg/kg, Imalgene , Merial, Lyon-France) diluted in distilled water, the back of 
the animals was shaved in order to put the area of interest more visible and cleaner. 
Subsequently, animals were placed in a stereotaxic frame and a small incision was 
made in the skin just to the right of the dorsal midline starting from the superior iliac 
crest. Then, the superficial muscular fascia was incised and the paraspinal muscles 
were separated by a combination of several lateral cuts until the right transverse 
processes of the lumbar vertebrae (L5 and L4) were achieved. Exposure was 
maintained using a surgery retractor and while using binocular magnification, the L4 
and L5 transverse processes were broken with a rongeur to access beneath them the 
L4 and L5 ganglia, which comprise the cell bodies of the sensory neurons that 
innervate the knee joint. The muscle and bone removal was minimised only to the 
enough to perform the intra-ganglionic injection. 
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A Hamilton syringe fitted with a glass capillary needle (coated with 
SigmaCote ) was used for the injection and the tip of all glass capillaries used was 
pulled to a small diameter to maintain the rigidity to penetrate DRG, with minimum 
damage. The Hamilton syringe was fixed to the stereotaxic frame (90º from 
horizontal) in order to move it downwards to allow the glass capillary needle to reach 
the DRGs. When the glass capillary needle was inside each DRG the syringe was 
slowly pushed to inject 3 µL of rAAV-SPRR1A, rAAV-GFP or saline. Posteriorly, 
the glass capillary needle was slowly withdrawn. 
 At the end of this procedure the wound was closed in layers (muscle and skin) 
using surgical sutures (4-0 Sutura cirúrgica de seda, Silkam). The intervened area was 
disinfected with Betadine ® (Meda Farma, Lisboa-Potugal) and all animals were 
rehydrated with a subcutaneous injection of 2 mL of 0.9 % saline (Braun, Queluz de 
Baixo-Portugal). The sedative effect of the anesthesia was reverted by an 
intramuscular injection of 0.02 mL/100 g of atipamezole hydrochloride (1 mg/kg; 
Antisedan ®, Esteve Farma, Carnaxide- Portugal). About half an hour after the 
reversal of the sedative effect, 0.1 mL of tramadol (Tramal ®, Grünenthal, Amadora-
Portugal) was orally administered to alleviate post-surgical pain.  
5. Behavioural Testing 
 The animals were accustomed to each of the behavioural tests used in this 
study for a minimum period of at least 4 days. Behavioural tests were performed in all 
animals in the same order (namely, 1st CatWalk, 2nd Von Frey, 3rd Knee-Bend and 
4th Rotarod) and at the following time points: 1) Before OA induction or saline 
injection (at day 0); 2) Before intra-ganglionic injections of AAV-GFP/AAV-
SPRR1A/saline (at days 7 and 14 after collagenase or saline knee injection); 3) After 
the intra-ganglionic surgical procedure (at days 21, 28, 35 and 42 after collagenase or 
saline knee injection), as depicted in Fig. 5. The behavioural analyses of AAV2/5-
SPRR1A animals are relative to 20 animals (control n=10 and OA n=10). Regarding 
the AAV-GFP animals, the behavioural analyses correspond to 10 animals (control 
n=5 and OA N=5), while the saline group comprises 4 animals (control n=2 and OA 
n=2). 
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Figure 5. Timeline for behavioural analyses. 
 5.1 CatWalk test- Assessment of movement-evoked pain 
 The CatWalk test consisted in placing the animals in a glass platform 
equipped with a light from LEDs located in a dark compartment. Animals were 
allowed to walk freely and a bright image, only at the points of contact of the paw 
with the surface, was produced. Under the glass platform, a video camera that was 
connected to a computer equipped with video acquisition software (Ulead Video 
Studio, Freemont, CA) monitored the animals` movements. The signal intensity 
depended on the area of the paw in contact with the platform and increased with the 
pressure applied by the paw. From the recorded videos, random frames were 
analysed: three pairs of frames (one for each hind paw) with the animal walking and 
three frames with the animal standing still. The number and intensity of pixels above 
a defined threshold were quantified, for each hind paw. This analysis was made with 
Image J software in order to determine the total hindpaw print intensity (mean pixel 
intensity x number of pixels). Results were expressed as the percentage of the total 
ipsilateral hindpaw print intensity (%TIPPI) in the total intensity of both hindpaw 
prints (Ferreira-Gomes et al., 2008). 
 5.2 Von Frey test- Assessment of mechanical allodynia   
 In the Von Frey test, animals were placed in a grid with small holes. The 
meshed grid allowed the application of the Von Frey filaments to the central region of 
the plantar surface of the animals´ hind paws. This stimulation was made in ascending 
order of force using the Touch Test Sensory Evaluator Kit (Stoelting, Wood Dale, 
USA)- 0.008g; 0.02g; 0.04g; 0.07g; 0.16g; 0.4g; 0.6g; 1.0g; 1.4; 2.0g; 4.0g; 6.0g; 
8.0g; 10.0g; 15.0g; 26.0; 60.0g; 100.0g; 180g; 300g. It was considered an escape 
response caused by pain when animals abruptly shacked the hindpaw and when they 
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1)               2)                 2)               3)                 3)                3)              3)            	   
Time  
(days) 
1
st
 
Collagenase/saline 
injection Intra-ganglionic 
injection of AAV-
SPRR1A, AAV-GFP 
or saline 
2
nd 
Collagenase/saline 
injection 
FMUP      
     Effect of SPRR1A overexpression on the nociceptive behaviour of OA animals 
     	  
27	  	  
licked it. The lowest value of force required to elicit a positive response was 
considered to be the paw withdrawal threshold (PWT). However, for each test 3 trials 
were performed, with a break of 2 minutes between each. The up-down method was 
the one used, i.e. in the absence of a paw withdrawal response to the selected hair, a 
stronger stimulus was presented, in the event of paw withdraw, the next weaker 
stimulus was chosen, as previously described (Bonin et al., 2014). 
 
 5.3 Knee-Bend test-Assessment of movement-evoked pain  
 The Knee-Bend test consisted in counting the number of squeaks and/or 
struggle reactions of the animals in response to alternate flexions and extensions of 
the knee joint. Both hind paws were evaluated and each test included 5 flexions and 5 
extensions. The score of the test was determined according to the type of reaction: 
Score 0 was given when there was no response to any kind of movement (flexion and 
extension); score 0.5 when there was struggle reaction in response to maximal 
flexion/extension; score 1 when there was struggle reaction in response to moderate 
flexion/extension and also when there were vocalizations in response to maximal 
flexion/extension and score 2 was given to squeak reactions in response to moderate 
movements (flexions and extensions) of the joint. The sum of the registered reactions, 
giving maximal values of 20, represents the Knee-Bend scores, an indication of the 
animal´s nociception. The contralateral knee was always evaluated first, in order to 
avoid an increase in the contralateral score arising from the manipulation of the 
injected knee (Ferreira-Gomes et al., 2008). 
 
5.4 Rotarod test- Assessment of motor coordination   
 The Rotarod test has been used to evaluate the motor coordination of the rats. 
This test consisted in placing the animals on a horizontal rod that rotates about its 
long axis and the time that the animals stayed without falling was recorded. The 
apparatus is configured to accelerate from 4 to 40 rpm in 300s, however, during the 
period of habituation the animals stayed in the apparatus at a constant speed of 4 rpm 
(Piel et al., 2014). 
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 6. Tissue Preparation        
 Naïve animals with rAAV-GFP injection were perfused at three different time 
points (4, 6 and 8 weeks after intra-ganglionic injection, n=3 for each time point) for 
later immunohistochemical analysis. OA and control animals with rAAV-SPRR1A 
(n=10, 5 OA and 5 control), rAAV-GFP (n=4, 2 OA and 2 control) and saline 
injections (n=4, 2 OA and 2 control) were euthanized by decapitation 6 weeks after 
model induction for gene expression studies.  
 
 6.1 Tissue processing for Immunohistochemistry     
 For the immunohistochemistry group, animals were intraperitoneally 
anesthetized with sodium pentobarbital (100 mg/kg, Eutasil ®, Ceva, Algés-Portugal) 
diluted in 0.9% saline and then perfused. The perfusion consisted in opening the 
abdominal and thoracic cavities in order to expose the heart. When exposed, 0.1 mL 
of heparin was injected into the left ventricle and a cannula was inserted in the aorta 
through an incision in the same ventricle. Thereby, about 300 mL of oxygenated 
Tyrode`s solution (wash solution) circulated followed by 800 mL of a fixative 
solution containing 4% paraformaldehyde (PFA) diluted in phosphate buffer saline 
0.1M (PBS 0.1 M). At the end of the perfusion the animals were dissected and L3, L4 
and L5 spinal cord segments were collected along with their roots and DRGs. The 
collected material was post-fixed for 4 hours in the same fixative solution and then 
kept in 30% sucrose with 0.01% sodium azide, until they were processed. 
 DRGs were serially sliced in 12µm thick sections, using a cryostat (Leica 
instruments GmbH, CM3050, Germany), and collected into poly-L-Lysine coated 
slides. Each DRG was collected in 6 sequential series, with an average of 12 sections 
per slide. After cutting, the slides were dried on a heating plate for 1 hour at 37ºC and 
thereafter were stored at -20ºC until use in immunohistochemical reactions. 
 
 6.1.1 Immunoreaction against GFP     
 The slides containing the L4 and L5 DRG slices of naïve animals intra-
ganglionically injected with rAAV-GFP sacrificed at different time points (4, 6 and 8 
weeks after surgery) were thawed and washed firstly in PBS 0.1M and then in PBST. 
Then, sections were incubated with the blocking solution (10% Normal goat serum, 
NGS, diluted in PBST) to avert unspecific ligations. After, the sections were 
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incubated overnight in the primary antibody against GFP (polyclonal rabbit anti-GFP; 
1:1000, Abcam, USA) diluted in PBST containing 2% NGS. In the next day, the 
sections were washed in 2% NGS in PBST and incubated in the dark in the secondary 
antibody (Alexa 594 goat anti-rabbit; 1:1000; A11012 Life Technologies, Eugene, 
USA) diluted in PBST containing 2% NGS. From this moment on the slides were 
always protected from light, being washed in PBST followed by PBS and stored in 
PBS 0.1M at 4ºC until visualization under the fluorescent microscope. At the time of 
microscopic analysis, the slides were coverslipped with a glycerol solution prepared 
with PBS 0.4M. Microscopic analysis was performed by using a fluorescent 
microscope (AXIO Imager.Z1, Zeiss, Germany) coupled to a digital camera 
(Axiocam MRm, Zeiss, Germany) and an image software (Axiovision 4.8 software, 
Carl Zeiss MicroImaging) to capture the images. The total number of cells was 
counted as well as the number of GFP labelled cells. This was performed with the aid 
of Image J ® computer program. Data is presented as the percentage of cells 
expressing GFP in L4 and L5 DRG. 
 6.1.2 Double immunoreaction against GFP and GFAP   
 In order to analyze if the rAAV transfected not only neurons, but also satellite 
glial cells, a colocalization of GFP with GFAP was performed. This double reaction 
was made in slides containing the L4 and L5 DRG slices of naïve animals intra-
ganglionically injected with rAAV-GFP. L4 and L5 slices were thawed and washed in 
PBS 0.1M and PBST. After this, sections were incubated with blocking solution (10% 
NGS in PBST) and then immunoreacted against GFP (rabbit anti-GFP; 1:1000, 
Abcam, USA) and GFAP (mouse anti-GFAP; 1:1000, Cell Signaling, Netherlands) 
during 24h. Sections were then washed in 2% NGS diluted in PBST and incubated in 
the dark with secondary antibodies (Alexa 488 donkey-anti-mouse; 1:1000; A21202 
Molecular Probes, Eugene, USA and Alexa 594 goat-anti-rabbit; 1:1000; A11012 
Life Technologies, Eugene, USA) diluted in PBST containing 2% of NGS. Lastly, 
sections were washed in PBST followed by PBS and stored in PBS 0.1M at 4ºC until 
visualization under the fluorescent microscope. At the time of microscopic analysis, 
the slides were coverslipped with glycerol prepared with PBS 0.4M.  
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 6.2 Tissue processing for real time quantitative polymerase chain reaction   
 (real time qPCR)         
 For the gene expression studies the animals were euthanized by decapitation 
after being slightly sedated with isoflurane. Their L3-L5 ipsilateral and contralateral 
DRGs as well as their corresponding spinal cord segments were fleshly harvested into 
RNase free eppendorfs, immediately put on ice and preserved at -80ºC until further 
use. The L4 and L5 DRGs, of each side, were pooled together.  
 
 6.2.1 RNA extraction       
 Total RNA was extracted using the RNAqueous-MicroTotal isolation Kit 
(Ambion). Briefly, 100 mL of lysis buffer was added to the samples, and they were 
homogenized using magnetic beads and centrifuged at 21000 g for 5 min. The cleared 
supernatant was transferred to a new RNase-free tube and the half volume of 100% 
ultra pure ethanol was added. Samples were briefly vortexed and then transferred to a 
micro filter cartridge. After, samples were centrifuged at 12000 g for a few seconds in 
order filter the protein from the RNA. Afterwards, the protein was discarded and a 
new collection tube was applied to the micro filter cartridge. The samples were 
washed with 180 µL of wash solution 1 (provided with Ambion isolation Kit) and 
centrifuged during a few seconds. Then, samples were washed with 180 µL of wash 
solution 2/3 (provided with Ambion isolation Kit) followed by centrifugation during a 
few seconds. This wash was repeated once. After dumping the collector tube, the 
micro filter cartridge was replaced into the same collection tube and centrifuged 
during 2 min to remove residual fluid and dry the filter. Finally, the micro filter 
cartridge was transferred to a micro elution tube (1.5 ml tubes provided with the kit) 
and 10µL of the elution solution, preheated to 75ºC, was added. A centrifugation was 
made for a few seconds and RNA was eluted from the filter. This elution step was 
repeated with a second 7µL aliquot of elution solution, collecting the eluate in the 
same micro elution tube. The micro filter cartridges were discarded and the micro 
elution tubes were stored. RNA was quantified by NanoDrop 2000 (Thermo Scientific 
NanoDrop 2000 spectrophotometer) and its integrity was assessed (absorbance 
260/280 and 260/230 ratios). 
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 6.2.2 cDNA synthesis       
 1,5 µg of total RNA was reversed transcribed using the Tetro cDNA synthesis 
kit (Bioline, A meridian Life Science ®, USA) and random primers. In each reaction 
1µL of Oligo(dt)18 primer, 1µL of 10 nM dNTP mix, 4µL of RT buffer, 1µL of Rnase 
inhibitor and 1µL of Tetro reverse transcriptase were added to a total mix of 12µL of 
water and RNA (12-VRNA = VMilliQ water. ). Samples were incubated at 45ºC for 50 min 
followed by 85ºC for 3 min in a Biorad T100 Thermal Cycler. The resulting cDNA 
was diluted 1:3 and stored at -20ºC for later use. 
 
 6.2.3 Real-time qPCR      
 Relative gene expression levels were measured by real-time qPCR using the 
StepOnePlus Real-time PCR system (Applied Biosystems). The PCR mix was 
prepared by adding 7µL of SYBR ® Select Master Mix (Applied Biosystems), 1µL of 
the primer mix, 5µL of MilliQ water and 1µL of cDNA sample for a final volume of 
14µL. Each PCR mix was prepared in triplicate. Primer sequences are listed in Table 
2. The reaction plate was sealed, centrifuged briefly and placed in the Real-Time PCR 
system. The amplification protocol consisted in forty cycles with denaturation at 95ºC 
for 15s, followed by annealing at 60ºC for 30s and extension at 72ºC for 30s. Target 
gene expression was normalized against to the expression of the endogenous 
glyceraldehyde-3-phosphate dehydrogenase (Gadph). 
 
Transcript Primers sequences 
SPRR1A F: GAGCCTGCTCTTCTCTGAGTATT 
R: TGAGGGGGTACAGTGCAAGG 
ATF-3 F: CCAGAACAAGCACCTTTGCC 
R: GTTTCGACACTTGGCAGCAG 
GFAP F: AATTGCTGGAGGGCGAAGA 
R:TTGAGGTGGCCTTCTGACAC 
GAPDH F: CCATCACCATCTTCCAGGAG 
R: GCATGGACTGTGGTCATGAG 
 
Table 2. Primers sequences for real-time qPCR; F: forward primer; R: reverse primer 	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7. Histological analysis of the knee joints     
  The use of calcified bone samples allows the bone mineral phase to be 
intact. Methylmethacrylate has been widely used as an ideal medium to soak calcified 
bone because of its hardness (Dominguez et al., 2012). The knee joints of the control 
and OA animals that were used to study gene expression were dissected and 
immersed in 70% alcohol in glass vials during three days, with daily change. In the 
next three days, the knees were immersed in 100% alcohol, with daily change. This 
dehydration was performed to promote the removal of water from the tissue and to 
allow subsequent infiltration of the resin. The next step was the diaphanization for 
total waste elimination and to allow the best favourable tissue conditions for resin 
infiltration. Thus, knees were immersed in a xylene solution during 8-12 hours. 
Infiltration is the time required for the methyl methacrylate resin (MMA) to dissipate 
throughout the sample by filling the tissue. This infiltration consists of phases A and 
B, and inclusion is made in a phase C. The solution of phase A is constituted by 75% 
of MMA (Merck , C5H8O2, Darmstadt- Germany) and 25% of Dibutylphthalate 99% 
(DF) (Sigma-Aldrich , C16H22O4, St. Louis- USA). The knees remained in this 
solution for three days at 4ºC, with daily change. In a next phase solution A was 
replaced by a solution B with 75% of MMA, 25 % of DF and 1g of Benzoyl peroxide 
(BP) (Merck , C14H10O4, Darmstadt- Germany), remaining three days at 4ºC with 
daily change. The last phase (C) was the inclusion in a solution comprising 75% of 
MMA, 25% of DF and 2.5g of BP. This solution was daily changed and on the third 
day the glass vials with the knees and with inclusion solution were placed in the oven 
at 37 ºC until polymerization. After polymerization of the resin, the glass vials that 
served as a template for inclusion were carefully broken allowing the microtomy of 
the block. The microtomy was done using an automatic microtome (Leica, RM 2255) 
with a tungsten blade and the blocks were cut into 5 µm sections into glass slides, and 
allowed to adhere to the slides in an oven during 24h.     
 Knee joint sections were stained by the Fast Green and Safranin-O method to 
evaluate the extent of the histopathological lesions, as previously described (Ferreira-
Gomes et al., 2012). Briefly, the staining protocol consisted in keeping the slides with 
the knee joint sections during 15 minutes in a 0.02% Fast Green solution, followed by 
a brief incubation of 30s in acetic acid. Then, the slides were maintained during 5 
minutes in 0.5 % Safranin. Finally, the slides were washed in distilled water and kept 
FMUP      
     Effect of SPRR1A overexpression on the nociceptive behaviour of OA animals 
     	  
33	  	  
in the oven overnight to dry. After drying, slides were mounted with Entellan® 
(Merck, Darmstadt-Germany) and images were acquired with an Axioskop-40 
microscope equipped with a Camera (Leica EC3 Microsystems, Switzerland).   
 Safranin O staining is directly proportional to the concentration of 
proteoglycan in the cartilage and the acidic Fast Green can bind to the collagen fibres 
in the subchondral bone. Therefore, this type of staining is a good approach to reveal 
the pathological changes in the knee joints (Ferreira-Gomes et al., 2012). 
 
8. Statistical Analysis       
 Statistical analyses were performed using the GraphPad Prism Software 
Version 6.0 for Macintosh. Results were presented as the mean ± SEM. For the 
number of GFP expressing cells (immunohistochemistry reactions) an unpaired t-test 
was performed to investigate differences on GFP expression in DRGs with different 
times of AAV transduction. Behavioral data was analyzed by a two-way analysis of 
variance (ANOVA) followed by the Bonferroni post-hoc test for comparisons 
between control and OA groups, between ipsilateral and contralateral sides and also 
between ipsilateral sides from different groups at each time-point. For comparisons 
within the same group repeated measures followed by Bonferroni post-hoc test was 
used. Gene expression data were analyzed by one-way ANOVA. In all statistically 
analysis the level of significance was considered as p<0.05. 
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Results 
1. Evaluation of AAV2/5 transfection efficiency 
 In order to evaluate the best time for an efficient AAV2/5 transfection, DRGs 
of naïve animals with different times of AAV2/5-GFP transfection (4, 6 and 8 weeks 
after intra-ganglionic injection) were immunolabelled against GFP. 
Immunofluorescence results showed no significant differences in the transduction 
efficiency between the three time-points studied (Fig. 6C). Therefore, the 4 weeks of 
transduction was chosen for the remaining studies. 
 
 
 
 
 
 
 
 
 
 
Figure 6. GFP expression in the DRG. A, B- Fluorescent microscope photos images 
depicting the neuronal populations transduced by AAV-GFP during 4 weeks. A- 2,5x 
magnification, scale bar represents 200 µm; B- 10x magnification, scale bar represents 50 
µm. C- Immunofluorescence analysis of GFP expression in L4 and L5 DRGs injected with 
AAV2/5-GFP, and collected at different time points (4, 6 and 8 weeks after intra-ganglionic 
injection) Results are presented as the percentage of GFP labelled neurons in L4 and L5 
DRG. Mean ± SEM. Unpaired t-test. No significant differences were found between the three 
time points evaluated. 
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2. Determination of AAV2/5 transfection in Satellite glial cells (SGC) 
 To investigate if, beyond neurons, AAV2/5 also transfects SGCs, ipsilateral 
L4 and L5 DRGs of naïve animals receiving an AAV-GFP intra-ganglionic injection 
were immunoreacted against GFP and GFAP (marker of activated satellite glial cells). 
No colocalization between GFP and GFAP was detected in our DRG samples, ruling 
out the possible transfection of SGC by AAV2/5 (Fig. 7).  
 
Figure 7. Double immunoreaction against GFP and GFAP. Fluorescent microscope photo 
images depicting a double immunoreaction against GFP (red, labelling the neuronal cell 
bodies) and GFAP (green, labelling the surrounding SGCs) in a L4 DRG with 4 weeks of 
AAV2/5-GFP transfection. No co-localization was observed. Scale bar represents 10 µm (40x 
magnification). 
3. Evaluation of the animals´ behaviour following intra-ganglionic 
injection of AAV-GFP or of saline  
 After ascertaining that the best time for an efficient transfection of the 
AAV2/5 was 4 weeks, intra-articular injections of saline (control animals) and 
collagenase (OA animals) were performed in the right knee of a new animal group. 
After 14 days animals were intra-ganglionically injected with AAV2/5-GFP or saline. 
The AAV-GFP group was used as control of AAV-SPRR1A injections and the saline 
group as a control of the intra-ganglionic injection. The nociceptive behaviour of the 
animals was evaluated, during 4 weeks, by the CatWalk and the Knee-Bend tests, 
which assess movement- and loading-evoked pain, as well by the Von-Frey test that 
evaluates mechanical allodynia. Moreover, the motor coordination was also verified 
by the rotarod test.  
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                   3.1 Evaluation of movement evoked pain - CatWalk test 
 In both the saline and AAV-GFP groups there were significant differences 
between control and OA animals till day 14. In the OA group significant differences 
were also found at 7 and 14 days in comparison with t0, as expected, confirming the 
development of nociception due to OA induction. After the surgical procedure, i.e. 
after the AAV-GFP or the saline intra-ganglionic injection, these values remained 
stable throughout the entire duration of the study (Fig. 8A and B). 
 
Figure 8. Evolution of the percentage of the ipsilateral paw-print total intensity of 
animals intra-ganglionically injected with AAV2/5-GFP or saline. Viral or saline intra-
ganglionic injections were performed at 14 days (dashed lines) after collagenase or saline 
intra-articular injections. Graph A and B correspond to the behaviour of animals with intra-
ganglionic injection of AAV-GFP and saline, respectively. Mean ± SEM, two-way ANOVA 
followed by Bonferroni post-hoc test for comparisons between the control and collagenase 
groups at each time-point, *p <0.05; **p<0.01; ***p<0.001; ****p<0.0001. Repeated-measures 
followed by Bonferroni post-hoc test for comparisons within the same group, δp<0.05; 
δδδp<0.001; δδδδp<0.0001 significantly different from t0. 
 3.2 Evaluation of movement evoked pain - Knee-Bend 
 Control animals with intra-ganglionic injection of AAV-GFP (Fig. 9A) and 
saline (Fig. 10A) showed no differences in the Knee-Bend score throughout the study 
except at day 21, the first behavioural testing day after the intra-ganglionic injection, 
when an increase in the ipsilateral Knee-Bend score was observed (Fig. 9A and 10A). 
Regarding OA animals injected with AAV-GFP, an increase in the ipsilateral Knee-
Bend score was observed at days 7 and 14, remaining relatively stable thereafter, with 
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no significant differences regarding to t14, and significantly different from the 
contralateral knee except at day 28 (Fig 9B). In the OA group of saline intra-
ganglionic injection there was also an increase in the Knee-Bend score when 
compared to the contralateral knee and to t0, though not statistically significant (Fig. 
10B). When comparing the Knee-Bend scores of the ipsilateral knees between OA 
and control animals after GFP injection significant differences were detected 
throughout the study, particularly at days 21, 35 and 42 after intra-articular injection 
(Fig. 9C). 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Knee-Bend scores of animals intra-ganglionically injected with AAV2/5-GFP. 
Knee-Bend scores of animals with saline intra-articular injection (control, A), animals 
injected with 500U of collagenase (OA, B) and Knee-Bend scores of osteoarthritic and 
control animals, only in the ipsilateral paw (C). Dashed line represents viral injections. Mean 
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± SEM, two-way ANOVA followed by the Bonferroni post hoc test for comparisons between 
the ipsi- and contralateral sides or between groups at each time-point, *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001. Repeated-measures followed by Bonferroni post-hoc test for 
comparisons within the same group, ++P<0.01, significantly different from t14 and δδp<0.01; 
δδδδp<0.0001, significantly different from baseline levels (t0). 
 
 
 
 
 
 
 
Figure 10. Knee-Bend scores of animals intra-ganglionically injected with Saline. Knee-
Bend scores of animals with saline intra-articular injection (control, A), animals injected with 
500U of collagenase (OA, B) and Knee-Bend scores of osteoarthritic and control animals, 
only in the ipsilateral paw (C). Dashed line represents saline intra-ganglionic injections. Mean 
± SEM, two-way ANOVA followed by the Bonferroni post hoc test for comparisons between 
the ipsi- and contralateral sides or between groups at each time-point. Repeated-measures 
followed by Bonferroni post-hoc test for comparisons within the same group. No significant 
differences were found. 
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 3.3 Assessment of mechanical allodynia - Von Frey test  
 The control animals of both groups (GFP and saline) did not show any 
significant differences in the PWT throughout the study as well as nor between the 
ipsilateral and contralateral sides (Fig. 11A and 12A). The OA animals showed a 
decrease in the ipsilateral PWT from day 0 onwards, that was significantly different 
form the contralateral side at some time-points (Fig 11B and 12B). In the GFP group 
these differences were statistically significant at 21 days (p<0.01), with a decrease in 
PWT of ipsilateral paw after intra-ganglionic injection, and at 42 days (p<0.05) (Fig. 
11B). In the saline group the significant differences between the contralateral and 
ipsilateral sides were observed at 21 days (p<0.01) and at 35 days (p<0.01) (Fig. 
12B). When comparing the ipsilateral sides between the OA and control animals of 
saline and GFP groups there were no statistically differences in PWT (Fig. 11C and 
12C), although in the GFP group the PWT of OA animals was always inferior to that 
of control animals. 
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Figure 11. Paw withdrawal threshold (PWT) to Von Frey filaments of animals intra-
ganglionically injected with AAV2/5-GFP. PWT of animals with saline intra-articular 
injection (control, A), animals injected with 500 U of collagenase (OA, B) and of 
osteoarthritic and control animals, only in the ipsilateral paw (C). Dashed line represents 
AAV2/5-GFP intra-ganglionic injections. Mean ± SEM, 2-way ANOVA followed by the 
Bonferroni post-hoc for comparisons between the ipsilateral and contralateral sides or 
between groups at each time point *p<0.05; **p<0.01. Repeated-measures followed by 
Bonferroni post-hoc test for comparisons within the same group was also performed but no 
statistically significant differences were found. 	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Figure 12. Paw withdrawal threshold (PWT) to Von Frey filaments of animals intra-
ganglionically injected with saline. PWT of animals with saline intra-articular injection 
(control, A), animals injected with 500 U of collagenase (OA, B) and of osteoarthritic and 
control animals, only in the ipsilateral paw (C). Dashed line represents saline intra-ganglionic 
injections. Mean ± SEM, 2-way ANOVA followed by the Bonferroni post-hoc for 
comparisons between the ipsilateral and contralateral sides or between groups ate each time 
point *p<0.05. Repeated-measures followed by Bonferroni post-hoc test for comparisons 
within the same group was also performed but no statistically significant differences were 
found. 
 3.4 Assessment of motor coordination - Rotarod test 
            There were no significant differences in the permanence time of animals in the 
rotarod, between OA and control animals of both groups (GFP and saline) throughout 
the study (Fig. 13 A and B).	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Figure 13. Permanence in Rotarod in seconds (s) of control and osteoarthritic animals 
following saline and AAV-GFP injections. The dashed line represents the intra-ganglionic 
injection of GFP (A) or saline (B). Mean ± SEM, 2-way ANOVA followed by the Bonferroni 
post-hoc test for comparisons between groups at each time-point. Repeated-measures 
followed by Bonferroni post-hoc test for comparisons within the same group. No significant 
differences were found. 
4. Evaluation of animals´ behaviour following AAV-SPRR1A intra-
ganglionic injection  
  At 14 days after saline or collagenase intra-articular administration an intra-
ganglionic injection of AAV2/5-SPRR1A was performed in another group of control 
and OA animals. The animals were then subjected to the same behavioural tests 
performed in the AAV-GFP and saline groups.  
 
              4.1 Evaluation of movement evoked pain- CatWalk test 
 The CatWalk test was always performed first to minimize the effect of the 
manipulation of the affected knee joint in the gait of the animal. CatWalk data are 
presented as the percentage of the total paw print intensity (%TIPPI) (Fig. 15). 
Throughout the study, the control animals showed no significant changes in the paw 
print intensity (Fig. 14 A and C and Fig. 15). Contrariwise, in animals with OA a 
decrease of the %TIPPI was observed at 7 days, corresponding to an expected 
development of OA-associated movement and loading nociception due to collagenase 
injection (Fig. 15), which was significantly different from baseline (t0) (p<0.0001). 
This can be observed in Fig. 14B showing that at 7 days after collagenase injection 
the area of the ipsilateral paw in contact with the floor was reduced. Differences in 
comparison to baseline remained significant at 14 days (p<0.001), before intra-
ganglionic injection of AAV2/5. After AAV2/5 injection control animals did not 
show any differences in %TIPPI, while in OA animals an increase in %TIPPI was 
observed from day 28 till the end of the study, , although not reaching significance 
when compared to t14.  
 As expected, significant differences were observed in %TIPPI between the 
control and OA animals, especially at early time-points (t7, p<0.0001). These 
differences started to decrease with the course of the study (p<0.05 at 14, 21 and 35 
days). In fact, in the last day of the test, when SPRR1A is transduced at higher levels, 
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A B 
C D 
there were no significant differences between control and OA animals, with values of 
% of ipsilateral intensity being very similar in the two groups (Fig. 15).  
 
 
 
 
 
 
 
 
Figure 14. Image of paw prints of control (A and C) and osteoarthritic animals injected 
with 500U of collagenase (B and D). Images A and B correspond to 7 days after saline and 
collagenase injections, respectively and images C and D correspond to 4 weeks (28 days) 
after AAV2/5-SPRR1A intra-ganglionic injection. 
 
 
 
 
 
 
Figure 15. CatWalk data were expressed as the percentage of total ipsilateral paw print 
intensity (%TIPPI). Viral injections were performed at 14 days (dashed line) after 
collagenase or saline injection. Mean ± SEM, two-way ANOVA followed by the Bonferroni 
post-hoc test for comparisons between the control and collagenase groups at each time-point, 
*p<0.05; ****p< 0.001. Repeated-measures followed by Bonferroni post-hoc test for 
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comparisons within the same group, δδδδ p<0.0001,δδδp<0.001, significantly different from 
baseline levels. 
            4.2 Evaluation of movement evoked pain - Knee-Bend test  
 The Knee-Bend test was also used to evaluate movement-induced nociception 
and the results are presented as a Knee-Bend score. There were no significant changes 
in the Knee-Bend score between the ipsilateral and contralateral knees of control 
animals during the study; nevertheless, the ipsilateral knee showed slightly higher 
values (non-significant) after intra-ganglionic injection (t14) in the ipsi L4 and L5 
ganglia (Fig. 16A). In contrast, in the OA group there were significant differences in 
the Knee-Bend score between the contralateral and ipsilateral knees, as expected. A 
statistically significant increase in the ipsilateral Knee-Bend score (p<0.0001) 
regarding to baseline scores (t0) was observed, confirming a proper induction of OA 
and of the associated nociception, values remaining highly significant in the 
ipsilateral knee until 1 week after AAV2/5 injection (day 21; p<0.0001). Thereafter, 
the ipsilateral Knee-Bend score values start to decrease and at 4 weeks (t42) after 
intra-ganglionic injection of the AAV2/5-SPRR1A the differences between both 
knees, although significant, were much more attenuated (p<0.001). In fact, after 
SPRR1A injection at day 14, the ipsilateral Knee-Bend score at 35 days (3 weeks 
after AVV2/5-SPRR1A delivery) and at 42 days, the last day of the study, were 
significantly different from t14 (p<0.01 and p<0.001, respectively for days 35 and 42; 
Fig. 16B). When comparing the ipsilateral Knee-Bend score of control and OA 
animals, it was observed a decrease of the differences between both groups 
throughout the study, so that significant differences between the ipsilateral score of 
the two groups were no longer detected at 42 days (Fig. 16C). 
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Figure 16. Knee-Bend scores of animals intra-ganglionically injected with AAV2/5-
SPRR1A. Knee-Bend scores of animals injected with sterile saline (control, A), animals 
injected with 500 U of collagenase (OA, B) and Knee-Bend scores of osteoarthritic and 
control animals, only of the ipsilateral paw (C). The dashed lines represent the intra-
ganglionic injections of AAV-SPRR1A. Mean ± SEM, 2-way ANOVA followed by the 
Bonferroni post-hoc test for comparisons between the ipsi and contralateral sides or between 
groups at each time-point, **p<0.01; ***p<0.001; ****p<0.0001. Repeated-measures followed by 
the Bonferroni post-hoc test for comparisons within the same group, δδδδp<0.0001, 
significantly different from baseline levels (t0) and ++p<0.01, +++p<0.001, significantly 
different from t14. 
 4.3 Assessment of mechanical allodynia - Von Frey test   
 Von Frey test was used to evaluate the mechanical allodynia of the animals 
and results are presented as paw withdrawal threshold (PWT). In control animals, a 
decrease in the PWT in the ipsilateral paw was observed after the intra-ganglionic 
injection (t14) being significantly different from t14 at t21 (p<0.001) and t28 (p<0.01), 
and also significantly different from the contralateral side at t21 (Fig. 17A). However, 
at the latter time-points the differences disappeared. Throughout the study, yet, no 
differences were observed in the contralateral PWT. In the OA group the contralateral 
side also showed similar PWT values throughout the study and the reductions 
observed on the ipsilateral side at 7 and 14 days were statistically different from 
baseline levels (p<0.0001) and from the contralateral paw (p<0.0001 and p<0.01, for 
the 7 and 14 days, respectively), demonstrating a successful OA induction. After 
AAV2/5 injection, although significant differences in the PWT between the ipsilateral 
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and contralateral sides were still observed, significant differences in ipsilateral PWT 
regarding to t14 were no longer detected, indicating an attenuation of mechanical 
allodynia (Fig. 17B). When comparing the ipsilateral side of both groups, highly 
significant differences were observed until t14 (p<0.0001), as expected. However, 
from this time onwards the differences between the ipsilateral sides become less 
evident until t42 (Fig. 17C). 	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 17. Paw withdrawal threshold (PWT) to Von Frey filaments of animals intra-
ganglionically injected with AAV2/5-SPRR1A. PWT to Von Frey filaments in control (A) 
and osteoarthritic animals (B). Graph C represents the PWT of the ipsilateral paw in both 
groups. The dashed lines represent the intra-ganglionic injections of AAV-SPRR1A. Mean	 
±SEM, 2-way ANOVA followed by the Bonferroni post-hoc for comparisons between the 
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the ipsilateral and contralateral sides or between groups at each time point *p <0.05; **p <0.01; 
***p<0.001; ****p<0.0001. Repeated-measures followed by the Bonferroni post-hoc test for 
comparisons within the same group, δδδδP<0.0001, significantly different from baseline levels 
(t0) and ++p<0.01, +++p<0.001, significantly different from t14. 
         4.4 Assessment of motor coordination- Rotarod test 
  No differences were observed throughout the study in none of the two groups of 
animals as well as no differences between them. These results showed that the 
locomotor capacity of the animals was not compromised by the AAV-SPRR1A intra-
ganglionic injections (Fig. 18) 
 
 
 
 
 
 
 
 
Figure 18. Permanence on Rotarod in seconds (s) of control and osteoarthritic groups 
following AAV2/5-SPRR1A. The dashed line represents the intra-ganglionic injection of 
AAV-SPRR1A. Mean ± SEM, 2-way ANOVA followed by the Bonferroni post-hoc test for 
comparisons between groups at each time-point. Repeated-measures followed by Bonferroni 
post-hoc test for comparisons within the same group. No significant differences were found. 
 5. Behaviour of osteoarthritic animals of all groups (SPRR1A, GFP 
and saline) 
   
 When comparing all the OA animals used, after intra-ganglionic injection of 
AAV-SPRR1A, AAV-GFP or saline, significant differences between the AAV-GFP 
and AAV-SPRR1A groups were observed immediately 1 week after the injections 
(p<0.05 at 21 days) in the CatWalk test, with the AAV-SPRR1A animals showing an 
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increase in the % of TIPPI that remained until the end of the study (p<0.0001 at day 
42). In fact, at 42 days the SPRR1A group was also highly significantly different from 
the saline group (p<0.001; Fig. 19A). In the Knee-Bend test, as well as in the Von 
Frey test, there were no statistically significant differences between groups (Fig. 19B 
and C). In the rotarod test there were only significant differences between the 
SPRR1A and saline groups at 28 days of the study (Fig. 19D). 
 
Figure 19. Behaviour of OA animals of SPRR1A, GFP and saline groups. CatWalk data 
of OA animals (A). Ipsilateral Knee-Bend scores of OA animals (B). Paw withdrawal 
thresholds (PWT) in the ipsilateral side of OA animals (C) and time of permanence in the 
rotarod apparatus of the OA animals (D). Mean ± SEM, 2-way ANOVA followed by the 
Bonferroni post-hoc test for comparisons between groups at each time-point, *p<0.05; 
**p<0.01; ****p<0.0001 for differences between the SPRR1A and GFP groups; δp<0.05; 
δδδp<0.001 for differences between the SPRR1A and saline groups 
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6. Evaluation of gene expression 
      6.1 Real time qPCR for SPRR1A 
 Gene expression analysis in L4 and L5 DRGs by real time qPCR was 
employed to evaluate and confirm the overexpression of SPRR1A after intra-
ganglionic injection of AAV-SPRR1A. Furthermore, SPRR1A mRNA levels were 
also quantified in L4 and L5 DRGs of animals submitted to intra-ganglionic injections 
of saline and AAV-GFP. Results showed high levels of SPRR1A overexpression in 
L4 and L5 ipsilateral DRGs of control and OA animals following AAV-SPRR1A 
injection; however, the levels of overexpression were much higher in control animals 
(p<0.05; Fig. 20A). Regarding to the saline and AAV-GFP groups there was also an 
upregulation of the mRNA levels of SPRR1A in L4 and L5 ipsilateral DRGs of both 
control and OA animals (Fig. 20B and C). In the AAV-GFP group the ipsilateral 
DRGs of OA animals presented higher levels of SPRR1A expression comparatively 
to ipsilateral DRGs of control animals, although not statistically significant (Fig. 
20B). On the other hand, in the saline group the opposite occurred, with the 
expression of SPRR1A in ipsilateral DRGs of control animals being statistically 
greater than in OA animals (p<0.05; Fig. 20C). 
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Figure 20.  Gene expression studies for SPRR1A. The levels of SPRR1A mRNA 
expression in the L4 and L5 of control and OA animals with an intra-ganglionic injection of 
AAV-SPRR1A (n=10; 5 OA animals, 5 control animals) (A), AAV-GFP (n=4, 2 OA animals, 
2 control animals) (B) or saline (n=4, 2 OA animals, 2 control animals) (C) were measured by 
real time quantitative PCR. The expression of SPRR1A was assessed 4 weeks after intra-
ganglionic injections. Target gene expression was normalized to the expression of Gapdh. 
Mean ± SEM, one-way ANOVA followed by the Bonferroni post-hoc test, *p<0.05.  	  
            6.2 Real time qPCR for ATF-3 and GFAP 
 In L4 and L5 DRGs injected with AAV-SPRR1A, the mRNA expression of 
GFAP and ATF-3 genes was also evaluated. As previously stated, ATF-3 is described 
as being part of the same regeneration pathway of SPRR1A, while GFAP is a marker 
of SGCs activation that showed increased levels in DRGs innervating the knee joint 
after OA induction by collagenase intra-articular injection (Adaes et al., 2017). Our 
real time qPCR analyses showed an increase in the mRNA expression of GFAP and 
ATF-3 in ipsilateral L4 and L5 DRGs of control and OA animals, 4 weeks after intra-
ganglionic injection of AAV-SPRR1A. The expression of both genes was higher in 
ipsilateral DRGs of control animals (Fig. 21A and B), with the levels of ATF-3 
presenting statistically significant increases in comparison to those in OA animals 
(p<0.05; Fig. 21B). 
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Figure 21. Gene expression studies for GFAP and ATF-3. The expression of GFAP (A) 
and ATF-3 (B) in the ipsilateral and contralateral L4 and L5 DRGs of control (n=5) and OA 
(n=5) animals was measured by real time quantitative PCR, 4 weeks after intra-ganglionic 
injection of AAV-SPRR1A. Target gene expression was normalized to the expression of 
Gapdh. Mean ± SEM, one-way ANOVA followed by the Bonferroni post-hoc test, *p<0.05. 
7. Histological analysis of the knee joint 
 The Fast Green and Safranin O method was used to ascertain whether there 
were histopathological changes in the knee joints of OA animals following intra-
ganglionic injections of AAV-SPRR1A, AAV-GFP or saline. All OA animals showed 
a decrease in the proteoglycan content of the articular cartilage (Fig. 22A, B and C). 
Furthermore, OA animals injected with AAV-SPRR1A showed a slight erosion of the 
cartilage and consequent exposure of the subchondral bone (Fig. 22C). 
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Figure 22. Histopathology of knee sections from OA animals with intra-ganglionic 
injection of saline (A), AAV-GFP (B) or AAV-SPRR1A (C). Sections were stained with 
Safranin O and Fast Green. C-articular cartilage; SB-subchondral bone; M- meniscus. The 
black arrow in (C) indicates a slight erosion of the cartilage and consequent exposure of the 
subchondral bone in OA animals receiving an intra-ganglionic injection of AAV-SPRR1A. 
2,5x magnification. 	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Discussion 
 Osteoarthritis has become one of the most common health problems in the 
world and taking into account the inefficiency of treatments in the pain management it 
is extremely important to find out new treatment strategies. The expression of 
genes/proteins that may contribute to the regenerative capacity of the neurons has 
been shown to be altered in primary sensory neurons after peripheral lesions 
(Schreyer & Skene, 1993; Xiao et al., 2002). Furthermore, there are some studies 
demonstrating an increase in the SPRR1A expression after peripheral injuries (Bonilla 
et al., 2002; Starkey et al., 2009) and showing the role of its increase in promoting 
axonal outgrowth in DRG neurons (Bonilla et al., 2002). In an experimental model of 
knee OA induced by collagenase injection we also have found increased SPRR1A 
mRNA and protein levels in the ipsilateral DRG neurons (Adães et al., unpublished 
data). Altogether, these findings encouraged us to evaluate the effect of SPRR1A on 
the nociceptive behaviour of these OA rats. For that purpose we decided to use rAAV 
vectors to stimulate the overexpression of SPRR1A in primary sensory neurons. 
 Lately, rAAV vectors have been widely used in gene delivery on primary 
sensory neurons by direct injection into the DRG. Several AAV serotypes are used, 
yet, it was shown that the AAV2/5 has the best performance, transducing >90% of 
DRG neurons (Mason et al., 2010). In our investigation, we used this serotype to 
transfer our gene of interest (Sprr1a) into the DRG. Preliminary studies using other 
injection targets rather than the DRGs, such as knee joint, subcutaneous, intraspinal or 
intrathecal injections indicated that the best approach to achieve a satisfactory level of 
transfection efficiency would be to do intra-ganglionic injections, albeit being a 
highly invasive procedure. In order to find out the best time for an efficient 
transfection of AAV2/5, we started by doing intra-ganglionic injections of AAV2/5 
expressing the reporter gene GFP, and assessing different times of transduction (4, 6 
and 8 weeks after injection). Indeed, our results showed that at 4 weeks after injection 
a higher percentage of cells expressed GFP, with no significant differences regarding 
to the 6 and 8 weeks time points. These data showed a great efficiency of AAV2/5 in 
transfecting DRG neurons since it revealed a prolonged and stable transduction along 
time. A similar study using the AAV6 or AAV8 serotypes, and which assessed GFP 
expression 3 weeks and 3 months after intra-ganglionic injections, supported our data 
as no significant differences in the transduction rates were found in either serotypes 
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over time (Yu et al., 2013). However, other studies contradicted our result, since they 
showed a direct relationship between the transduction time of AAV2/5 (Mason et al., 
2010) and AAV8 (Fischer et al., 2011) and GFP expression. Although we have 
observed a high efficiency of AAV2/5 to transduce neurons, we did not analyse which 
type of neuronal populations in the DRG expressed GFP. Other studies by Mason and 
colleagues, however, demonstrated by double-immunolabelling of GFP with CGRP or 
with IB4, that both small peptidergic and small non-peptidergic neurons were 
transduced by AAV2/5 (Mason et al., 2010). For the purpose of investigating if 
AAV2/5 would also transduce satellite glial cells, beyond neurons, we did a double 
immunohistochemistry reaction against GFP and GFAP and co-localization was never 
observed. This result was corroborated by a study using the same serotype (Mason et 
al., 2010) and still by other using AAV6 and AAV8 (Yu et al., 2013). In controversy, 
Fischer et al injected AAV8-GFP intra-ganglionically and found evidence of SGCs 
transduction (Fischer et al., 2011). 
 To assess the consequences of AAV delivery to the cells as well as of the 
surgical injection procedure, intra-ganglionic injections of AAV-GFP and saline were 
performed in control animals. In fact, after intra-ganglionic injections of AAV-GFP 
the animals showed some evidences of increased nociception induced by movement 
(both in the CatWalk and Knee-Bend tests) and mechanical allodynia (Von-Frey test). 
However, these changes were slight and gradually resolved from the first week after 
injection. Some studies demonstrated a similar result, with animals showing a 
transient significant increase in mechanical allodynia after intra-ganglionic injections 
of AAV-GFP (Fischer et al., 2011; Samad et al., 2013). The animals with saline 
injections displayed also minor behaviours indicative of nociception induced by 
movement (in the Knee-Bend test) and no mechanical allodynia, and likewise, this 
hypersensitivity was progressively resolved from the first week after injection. 
However, Fisher and colleagues demonstrated that rats with PBS intra-ganglionic 
injection developed a temporary mechanical allodynia (Fischer et al., 2011). In 
addition to nociceptive behaviour, we also assessed the motor coordination by the 
rotarod test, which revealed that the locomotor capacity of animals was not 
compromised by both AAV-GFP and saline injections. Fisher et al., refuted, partially, 
our result, since they showed that animals revealed a progressive motor impairment 
after AAV injection, but after PBS injection the motor function was assured (Fischer 
et al., 2011). 
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 OA animals received as well AAV-GFP and saline injections in order to prove 
that the increased nociception developed with the disease would remain unaltered by 
these procedures. Actually, movement and loading-induced nociception and 
mechanical allodynia in OA persisted until the 42 days of the study, with no 
significant differences regarding to the day of injections (day 14 of OA). This result 
was corroborated by a comparable study using animals with spared nerve injury 
followed by AAV2/5-GFP DRG injection, where mechanical allodynia was shown to 
last over the entire studied time (Samad et al., 2013). Another study with intrathecal 
injection confirmed our result since injections of AAV-GFP and saline did not 
reversed the hypersensitivity shown after sciatic nerve constriction (Eaton et al., 
2002). Furthermore, the rotarod results showed that OA induction by collagenase 
intra-articular injection did not compromise the motor coordination of the animals, 
demonstrating that this is a suitable model for studying nociception associated to OA. 
Finally, although the surgical procedure caused transient changes on the nociceptive 
behaviour of control animals, this sensitization was minimal when compared to that 
caused by OA, and thus, intra-ganglionic injections seem to be an appropriate 
approach to study the efficacy of new treatments in chronic pain targeting the sensory 
ganglia.  
 Currently, several studies have focused on strategies to combat chronic pain 
through gene therapy. In line with this trend, the present study had as principal goal to 
check the contribution of SPRR1A overexpression on the nociceptive behaviour 
associated to osteoarthritis. Interestingly, following intra-ganglionic injections of 
AAV-SPRR1A, OA animals revealed a decrease on their nociceptive behaviour, 
hinting an antinociceptive effect of SPRR1A. Previous results indicating that after 
peripheral injury the increase on the SPRR1A expression promotes axonal outgrowth 
(Bonilla et al., 2002) together with this behavioral finding suggest that regenerative 
processes triggered with OA play, indeed, a role in attenuating the nociception 
associated with the pathology. To our best knowledge, there are no other studies 
associating SPRR1A to an antinociceptive effect, and therefore this constitutes a 
novelty that needs to be further addressed. However, other studies using AAV 
carrying other genes may be comparable to our. In fact, Samad et al showed that the 
use of DRG-targeted AAV-mediated knockdown of Nav1.3 channel by small hairpin 
RNA (shRNA) resulted in the remission of neuropathic pain in rats after spared nerve 
injury (Samad et al., 2013). Similarly, DRG injections of AAV8 carrying the 
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recombinant gene for the serine protease inhibitor 3, which is upregulated in DRG 
after nerve injury, showed as well a reduction of neuropathic pain-like behaviours in 
mice after spared nerve injury (Vicuna et al., 2015). In addition to the direct DRG 
injections, AAV injections through other routes have also proved an effect in reducing 
neuropathic pain. For example, the intraspinal delivery of rAAV2 carrying the gene 
for BDNF resulted in the reversal of neuropathic pain behaviour induced by chronic 
constriction injury (Eaton et al., 2002), and the intrathecal delivery of AAV8 serotype 
carrying IL-10 resulted in the reduction of neuropathic pain associated behaviour in a 
model of L5 spinal nerve ligation (Storek et al., 2008). Our results showed that the 
nociceptive behaviour in OA animals was only attenuated, and not totally reversed, 
which can be due to the hyperexcitability of L4 and L5 DRG neurons that were not 
infected by the AAV 2/5 (Samad et al., 2013). Even so, our data provide behavioural 
evidence for a contribution of SPRR1A in fighting pain in OA rats.  
 Concerning the gene expression studies we showed a big increase in SPRR1A 
mRNA levels in ipsilateral L4/L5 DRG of control and OA animals injected with 
AAV-SPRR1A. This result confirmed the ability of AAV2/5 to express SPRR1A in 
sensory neurons. Despite this, we found a rather surprising result, with an unequal 
SPRR1A expression between OA and control animals, with ipsilateral DRG of control 
animals revealing a much greater overexpression than ipsilateral DRG of OA animals. 
Exposure of cells to sub-optimal growth conditions can be considered as a stress and 
immediate responses are necessary to ensure the survival of cells in response to 
extracellular changes (de Nadal et al., 2011). So, a possible justification is the 
existence of a downregulation process occurring in OA animals as a compensatory 
mechanism. Indeed, SPRR1A was shown to be increased in ipsilateral DRG of OA 
animals (Adães et al., unpublished data) and its overexpression by AAV-SPPR1A 
injection may to cause a continuous axonal growth (exogenously induced) that is no 
longer necessary and which eventually may have consequences, which may lead to a 
SPRR1A downregulation as a counteraction. In addition, we were faced with another 
startling result, as the animals with AAV-GFP and saline injections revealed an 
increase in the mRNA levels of SPRR1A of the same magnitude order as that of the 
animals injected with AAV-SPRR1A. Although animals with saline injection show a 
greater upregulation of SPRR1A in ipsilateral DRG of control animals, as in animals 
with AAV-SPRR1A injection, AAV-GFP animals showed a greater upregulation of 
SPRR1A in ipsilateral DRG of OA animals. Thus, considering these data and 
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knowing the role of SPRR1A in regeneration after peripheral injury, the only 
reasonable explanation for this data is the invasiveness of the surgical procedure for 
intra-ganglionic injection, that per se may initiate a regenerative process in response 
to a possible DRG lesion, which in this case is manifested by an increase in the 
SPRR1A expression. 
 ATF-3 is considered a marker of neuronal injury (Tsujino et al., 2000) and 
more recently its expression has been associated to regenerative processes, since it 
was shown to promote neurite outgrowth in cultured adult DRG neurons (Seijffers et 
al., 2006). ATF-3 transgenic mice showed increased levels of SPRR1A in DRG 
(Seijffers et al., 2007) and likewise OA induction revealed an increase in the 
expression of SPRR1A within the ATF-3 population (Adães et al., unpublished data). 
These reports suggest a relationship between both genes and the possibility of they 
belonging to the same regeneration-inducing signalling pathway. Similarly, our result 
goes in line with previous data showing as well a direct relationship between 
SPRR1A and ATF-3, since the SPRR1A overexpression seems to increase ATF-3 
levels. As in the data of SPRR1A overexpression, the ipsilateral DRG of control 
animals revealed a higher increase in the ATF-3 mRNA levels than ipsilateral DRG of 
OA animals. Thus, in addition to ATF-3 expression triggering an upregulation of 
SPRR1A (Seijffers et al., 2007), it seems that the opposite also happens, similarly to 
the relationship between SPRR1A and SOX11 (Jing et al., 2012). 
 After peripheral nerve injury, SGCs undergo activation, contributing to the 
maintenance of neuropathic pain (Takeda et al., 2009; Liu et al., 2012). It is known 
that after osteoarthritis induction by collagenase intra-articular injection there is glial 
activation in the DRG (Adaes et al., 2017) and furthermore, it is known that SGCs are 
also activated after direct DRG injections of saline (Puljak et al., 2009). Indeed, it is 
suggested that the activation of SGCs after intra-ganglionic injection is due to an 
inflammatory response triggered by the procedure. GFAP is a molecule that is up-
regulated in satellite glial cells when they are activated (Takeda et al., 2009) and, 
therefore, our results regarding the GFAP gene expression showed its increase in both 
ipsilateral DRG of OA and control animals following AAV-SPRR1A injection. 
Actually, the increase in GFAP expression was much lower than the increase in ATF-
3 expression, although it remained consistent with SPRR1A and ATF-3 expression, 
with a slightly higher increase in control animals. These data do not seem to be 
corroborated by above mentioned studies, since OA animals with intra-ganglionic 
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injections revealed less glial activation than control animals only with DRG injection. 
One possible explanation for this result, as in the case of ATF-3, is the existence of a 
relationship between SPRR1A and GFAP. Of course to test this hypothesis further 
studies will be necessary, since, so far both SPRR1A and GFAP appear to have 
opposing roles; while SPRR1A show an antinociceptive role, glial activation is 
associated with pain maintenance. 
 Through histological analysis of the knee joint it was possible to realize if the 
improvement in nociceptive behaviour of OA animals by AAV-SPRR1A injection 
correlated with a beneficial effect in the joint. However, the results were surprising, 
since, although all OA animals (OA with saline injection, OA with AAV-GFP 
injection and OA with AAV-SPRR1A injection) showed a decrease in the 
proteoglycan content of articular cartilage, the OA animals receiving AAV-SPRR1A 
showed also a slight erosion of the cartilage and exposure of the subchondral bone. 
Thus, these histological findings do not seem to explain the behavioural results. 
Several drugs have been shown to reverse the nociceptive behaviour of OA animals 
(Adaes et al., 2014), as well as to prevent articular degeneration (Kim et al., 2012). 
Furthermore, some studies suggest that the correlation between pain and structural 
changes may me not linear (Sofat & Kuttapitiya, 2014). Indeed, NSAIDs appear to 
have a positive effect on joint pain, like our data with the AAV-SPRR1A suggest, but 
can lead to destruction of the cartilage. Similar events might be occurring following 
SPRR1A overexpression, which possibly explain our finding of cartilage degeneration 
and subchondral bone exposure (Sofat & Kuttapitiya, 2014). 
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Conclusions 
 Primary sensory neurons have revealed to be an ideal target for therapeutic 
gene transfer and we believe that our work contributed to clarify the limitations of this 
type of approach, as well the role of SPRR1A overexpression on the nociceptive 
behaviour of OA animals.  
 
Molecular evidences 
 
AAV2/5 is extremely efficient in transducing neurons, but not SGCs. 
 The AAV2/5 serotype showed a prolonged and stable transduction, since there 
were no significant differences between the three time-points studied. Although there 
is some controversy, our result is in accordance with many studies that use other 
serotypes. Furthermore, based on our data we can conclude that this type of virus only 
transduces neurons (although we have not shown which subpopulations), and not 
SGCs. 
             
Intra-ganglionic injection promotes per se a regenerative process and the 
continuous growth triggered by SPRR1A overexpression induces a 
downregulation of SPRR1A in OA animals. 
 Our real time qPCR data showed an increase of SPRR1A mRNA levels of the 
same magnitude order in L4 and L5 DRG injected with AAV2/5-SPRR1A and in L4 
and L5 DRG injected with AAV2/5-GFP and saline. This unexpected result made us 
believe that the intra-ganglionic injection, because it is an invasive procedure, could 
initiate a regeneration process in response to a possible DRG lesion.  
 Moreover, we found an uneven SPRR1A expression between OA and control 
animals. L4 and L5 DRG injected with AAV2/5-SPRR1A of control animals showed 
much greater SPRR1A expression than ipsilateral DRG of OA animals. Taking into 
account these data we believe a downregulation process of SPRR1A in OA animals 
might be occurring as a compensatory event to ensure the survival of neurons, since 
too much SPRR1A could promote a continuous axonal outgrowth, which may have 
detrimental consequences.  
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SPRR1A showed a direct relationship with ATF-3 and GFAP.  
 ATF-3 and GFAP expression was observed in DRG after OA induction and in 
accordance with our data, both showed their highest mRNA levels in ipsilateral DRG 
of control animals, as SPRR1A. So, the possibility of SPRR1A and ATF-3 belonging 
to the same regeneration inducing signalling pathway is suggested by our result, since 
the SPRR1A overexpression seems to increase the ATF-3 levels. GFAP expression, 
although smaller than ATF-3 expression, remained consistent with SPRR1A and 
ATF-3 expression. Thereby, although SPRR1A is related to regeneration process and 
glial activation is associated with the maintenance of pain, there seems to be a 
relationship between SPRR1A and GFAP expression. 
 
Behavioural and Histological evidences 
 
DRG injection is a secure procedure. 
 Regarding to the procedure we can now conclude that, although it causes some 
behavioural changes, they are fleeting and slight and, therefore DRG injection is a 
secure procedure and a valuable tool in pain research. 
 
SPRR1A attenuates the nociceptive behaviour of OA animals. 
SPRR1A did not reverse the degradation of cartilage caused by OA. 
 SPRR1A seems to have an antinociceptive potential in OA animals, since it 
caused an attenuation of their nociceptive behaviour. However, despite these 
behavioural evidences, the histopathological findings did not reflect this, as the knee 
joints of OA animals receiving an AAV-SPRR1A injection showed slight erosion of 
the cartilage and exposure of the subchondral bone.  
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Future Perspectives 
 We are aware that additional experiments are necessary to clarify some of our 
hypotheses. Based in our data we need to evaluate which subtypes of neurons are 
transduced by the AVV2/5 to be able to confirm our results at the behavioural level. 
Likewise, we need to investigate the type of relationship between the activation of 
SGCs and the expression of SPRR1A.  
 Although intra-ganglionic injection of AAV2/5-SPRR1A in OA animals has 
shown attenuation on their nociceptive behaviour, the intra-ganglionic procedure 
showed some limitations, in so far as, control animals demonstrated slight nociceptive 
behaviour. Furthermore, the sharp rise in the SPRR1A mRNA levels after DRG 
injection of AAV-GFP and saline reveal the triggering of a regenerative process due 
to, probably, a DRG lesion inherent to the surgical procedure. For this reason, the 
implementation of a new approach would be important. Lopes et al., proposed an 
alternative approach to target peripheral neurons in vivo through the injection in the 
gastrocnemius muscles of nanoparticles to vectorize therapeutic genes. In this study, 
the injection of nanoparticles mediating the delivery of BDNF, followed by peripheral 
nerve crush injury, showed a recovery on the thermal nociceptive function and a delay 
in the allodynia development (Lopes et al., 2017). Furthermore, this method revealed 
that the BDNF mRNA levels were significantly increased in lumbar DRGs. Hence, 
this approach would be a good alternative to direct DRG injections. 
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Appendix 
 
Solutions preparation-general reagents 
 
o Collagenase  – 2,5mg of Type II collagenase from Clostridium histolyticum 
(Sigma-Aldrich ) diluted in 100 µl of 0,9% saline.  
o Tyrode´s solution- 6,8g of sodium chloride (NaCl), 0,40g of potassium 
chloride (KCL), 0,32g of hydrated magnesium chloride (MgCl2.6H2O), 0,1g of 
hydrated magnesium sulphate (MgSO4.7H2O), 0,17g of hydrated sodium 
dihydrogenophosphate (NaH2PO4.H2O), 1,0g of glucose and 2,2g of sodium 
hydrogenocarbonate (NaHCO3); add distilled water up to the final volume of 
1000 ml.  
o Sucrose solution 30% in Phosphate buffer 0,1M- 30g of sucrose diluted in 
phosphate buffer 0,1M to final volume of 1000 ml. 
o Phosphate buffer 0,4M (stock solution)- 26,2g of hydrated sodium 
dihydrogenophosphate (NaH2PO4.H2O), 140g of potassium 
hydrogenophosphate (K2HPO4) diluted in distilled water up to the final 
volume of 2500 ml. (pH between 7,2 and 7,4). 
o Phosphate buffer saline 0,1M (PBS)- 250 ml of phosphate buffer 0,4M and 
9g of sodium chloride (NaCl) diluted in distilled water up to 1L. 
o Phosphate buffer saline 0,1M with Triton X-100 (PBST)- 250 ml of 
phosphate buffer 0,4M and 9g of sodium chloride (NaCl) diluted in distilled 
water up to 1L. Add 12 ml of Triton-X-100 at 25%. 
o Solution A of Methylmethacrylate  – 75 ml of Methylmethacrylate and 25 
ml of Dibutyl phthalate to a final volume of 100 ml. 
o Solution B or 1% solution of Methylmethacrylate - 75 ml of 
Methylmethacrylate and 25 ml of Dibutyl phthalate and 1g of Benzoyl 
peroxide to a final volume of 100 ml. 
o Solution C or 2,5% solution of Methylmethacrylate - 75 ml of 
Methylmethacrylate and 25 ml of Dibutyl phthalate and 2,5g of Benzoyl 
peroxide to a final volume of 100 ml. 
o 0,02% Fast Green- 0,02g of Fast green diluted in distilled water up to 100 
ml. 
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o 0,5% Safranin- 0,5g of Safranin diluted in distilled water up to 100 ml. 
 	  	  	  	  	  	  	  	  	  	  	  	  
